WO2023230286A2 - Méthodes et compositions pour le traitement du cancer - Google Patents
Méthodes et compositions pour le traitement du cancer Download PDFInfo
- Publication number
- WO2023230286A2 WO2023230286A2 PCT/US2023/023618 US2023023618W WO2023230286A2 WO 2023230286 A2 WO2023230286 A2 WO 2023230286A2 US 2023023618 W US2023023618 W US 2023023618W WO 2023230286 A2 WO2023230286 A2 WO 2023230286A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- administering
- pharmaceutically
- subject
- hydrogen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 420
- 206010028980 Neoplasm Diseases 0.000 title description 129
- 239000000203 mixture Substances 0.000 title description 73
- 201000011510 cancer Diseases 0.000 title description 62
- 150000003839 salts Chemical class 0.000 claims abstract description 257
- 229940124291 BTK inhibitor Drugs 0.000 claims abstract description 181
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims abstract description 144
- 229960001507 ibrutinib Drugs 0.000 claims abstract description 144
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims abstract description 134
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 claims abstract description 91
- 229950009821 acalabrutinib Drugs 0.000 claims abstract description 90
- VADOZMZXXRBXNY-UHFFFAOYSA-N 8-cyclopentyl-2-[4-(4-methylpiperazin-1-yl)anilino]-7-oxopyrido[2,3-d]pyrimidine-6-carbonitrile Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC=C(C=C(C#N)C(=O)N2C3CCCC3)C2=N1 VADOZMZXXRBXNY-UHFFFAOYSA-N 0.000 claims abstract description 60
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 44
- 150000001875 compounds Chemical class 0.000 claims description 601
- -1 4-methyl piperazinyl Chemical group 0.000 claims description 184
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 171
- 125000000623 heterocyclic group Chemical group 0.000 claims description 160
- 125000000217 alkyl group Chemical group 0.000 claims description 152
- 229910052739 hydrogen Inorganic materials 0.000 claims description 151
- 239000001257 hydrogen Substances 0.000 claims description 151
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 146
- 125000003342 alkenyl group Chemical group 0.000 claims description 138
- 125000003118 aryl group Chemical group 0.000 claims description 137
- 125000000304 alkynyl group Chemical group 0.000 claims description 136
- 125000001072 heteroaryl group Chemical group 0.000 claims description 135
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 123
- 238000002560 therapeutic procedure Methods 0.000 claims description 92
- 239000002552 dosage form Substances 0.000 claims description 87
- 229910052736 halogen Inorganic materials 0.000 claims description 84
- 150000002367 halogens Chemical class 0.000 claims description 84
- 239000008194 pharmaceutical composition Substances 0.000 claims description 80
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 65
- 239000002775 capsule Substances 0.000 claims description 60
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 39
- 229910004749 OS(O)2 Inorganic materials 0.000 claims description 31
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 28
- 239000007787 solid Substances 0.000 claims description 28
- 230000002195 synergetic effect Effects 0.000 claims description 24
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 125000004193 piperazinyl group Chemical group 0.000 claims description 19
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 18
- 125000004076 pyridyl group Chemical group 0.000 claims description 18
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 229940125814 BTK kinase inhibitor Drugs 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 abstract description 28
- 210000004027 cell Anatomy 0.000 description 91
- 238000011282 treatment Methods 0.000 description 66
- 230000002354 daily effect Effects 0.000 description 61
- 239000003826 tablet Substances 0.000 description 59
- 206010006187 Breast cancer Diseases 0.000 description 53
- 208000026310 Breast neoplasm Diseases 0.000 description 52
- 108090000623 proteins and genes Proteins 0.000 description 41
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 35
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 34
- 101100356020 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) recA gene Proteins 0.000 description 34
- 101100042680 Mus musculus Slc7a1 gene Proteins 0.000 description 34
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 33
- 239000003814 drug Substances 0.000 description 32
- 230000000259 anti-tumor effect Effects 0.000 description 31
- 230000022131 cell cycle Effects 0.000 description 28
- 238000009472 formulation Methods 0.000 description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 201000010099 disease Diseases 0.000 description 22
- 102000015694 estrogen receptors Human genes 0.000 description 22
- 108010038795 estrogen receptors Proteins 0.000 description 22
- 229940124597 therapeutic agent Drugs 0.000 description 21
- 238000004458 analytical method Methods 0.000 description 20
- 102000003998 progesterone receptors Human genes 0.000 description 20
- 108090000468 progesterone receptors Proteins 0.000 description 20
- 238000011529 RT qPCR Methods 0.000 description 19
- 238000012054 celltiter-glo Methods 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 18
- 239000007788 liquid Substances 0.000 description 18
- 230000004044 response Effects 0.000 description 17
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 16
- 229940125904 compound 1 Drugs 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 238000001516 cell proliferation assay Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- FWZAWAUZXYCBKZ-NSHDSACASA-N 5-amino-3-[4-[[(5-fluoro-2-methoxybenzoyl)amino]methyl]phenyl]-1-[(2S)-1,1,1-trifluoropropan-2-yl]pyrazole-4-carboxamide Chemical compound COc1ccc(F)cc1C(=O)NCc1ccc(cc1)-c1nn([C@@H](C)C(F)(F)F)c(N)c1C(N)=O FWZAWAUZXYCBKZ-NSHDSACASA-N 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 229960004390 palbociclib Drugs 0.000 description 13
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 229950001573 abemaciclib Drugs 0.000 description 12
- 238000010199 gene set enrichment analysis Methods 0.000 description 12
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 description 12
- 238000011002 quantification Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 101000896657 Homo sapiens Mitotic checkpoint serine/threonine-protein kinase BUB1 Proteins 0.000 description 11
- 102100021691 Mitotic checkpoint serine/threonine-protein kinase BUB1 Human genes 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 10
- 241000287828 Gallus gallus Species 0.000 description 10
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 10
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 10
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 229950003687 ribociclib Drugs 0.000 description 10
- 206010039491 Sarcoma Diseases 0.000 description 9
- 230000006907 apoptotic process Effects 0.000 description 9
- 230000004900 autophagic degradation Effects 0.000 description 9
- 210000001185 bone marrow Anatomy 0.000 description 9
- 231100000682 maximum tolerated dose Toxicity 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 238000002648 combination therapy Methods 0.000 description 8
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 8
- 235000013601 eggs Nutrition 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 230000008595 infiltration Effects 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000009097 single-agent therapy Methods 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 241001024304 Mino Species 0.000 description 7
- 108091007960 PI3Ks Proteins 0.000 description 7
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 7
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 7
- 210000002257 embryonic structure Anatomy 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- 108010014380 Autophagy-Related Protein-1 Homolog Proteins 0.000 description 6
- 102100037799 DNA-binding protein Ikaros Human genes 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 6
- 101150016712 IKZF1 gene Proteins 0.000 description 6
- 238000003559 RNA-seq method Methods 0.000 description 6
- 102100039988 Serine/threonine-protein kinase ULK1 Human genes 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 125000006165 cyclic alkyl group Chemical group 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000007902 hard capsule Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 201000005962 mycosis fungoides Diseases 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000004614 tumor growth Effects 0.000 description 6
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 5
- 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 229960003677 chloroquine Drugs 0.000 description 5
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 5
- 229960004171 hydroxychloroquine Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 230000002438 mitochondrial effect Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000009758 senescence Effects 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000004408 titanium dioxide Substances 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 229940122815 Aromatase inhibitor Drugs 0.000 description 4
- 108091008875 B cell receptors Proteins 0.000 description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 description 4
- 108700020472 CDC20 Proteins 0.000 description 4
- 108091007914 CDKs Proteins 0.000 description 4
- 101150023302 Cdc20 gene Proteins 0.000 description 4
- 102100038099 Cell division cycle protein 20 homolog Human genes 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 4
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 4
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 4
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 4
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 4
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 4
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 4
- 230000033616 DNA repair Effects 0.000 description 4
- 230000020172 G2/M transition checkpoint Effects 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 239000012828 PI3K inhibitor Substances 0.000 description 4
- 101100010298 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pol2 gene Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 108700012920 TNF Proteins 0.000 description 4
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003886 aromatase inhibitor Substances 0.000 description 4
- 239000012822 autophagy inhibitor Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 229960001681 croscarmellose sodium Drugs 0.000 description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 239000005414 inactive ingredient Substances 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 229940057948 magnesium stearate Drugs 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 210000001685 thyroid gland Anatomy 0.000 description 4
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 4
- RNOAOAWBMHREKO-QFIPXVFZSA-N (7S)-2-(4-phenoxyphenyl)-7-(1-prop-2-enoylpiperidin-4-yl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide Chemical compound C(C=C)(=O)N1CCC(CC1)[C@@H]1CCNC=2N1N=C(C=2C(=O)N)C1=CC=C(C=C1)OC1=CC=CC=C1 RNOAOAWBMHREKO-QFIPXVFZSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- NEXGBSJERNQRSV-UHFFFAOYSA-N 2-[5-bromo-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]oxy-N-methylbenzamide Chemical compound BrC=1C(=NC(=NC=1)NC1=CC(=C(C(=C1)OC)OC)OC)OC1=C(C(=O)NC)C=CC=C1 NEXGBSJERNQRSV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100027667 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2 Human genes 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100035616 Heterogeneous nuclear ribonucleoproteins A2/B1 Human genes 0.000 description 3
- 101000854026 Homo sapiens Heterogeneous nuclear ribonucleoproteins A2/B1 Proteins 0.000 description 3
- 101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000011712 cell development Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 108091008039 hormone receptors Proteins 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 3
- 150000003893 lactate salts Chemical class 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000004014 plasticizer Substances 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 208000037821 progressive disease Diseases 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- 231100000402 unacceptable toxicity Toxicity 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- 229950007153 zanubrutinib Drugs 0.000 description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- PDGKHKMBHVFCMG-UHFFFAOYSA-N 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 PDGKHKMBHVFCMG-UHFFFAOYSA-N 0.000 description 2
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 2
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical group C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
- KOEUOFPEZFUWRF-LJQANCHMSA-N 4-amino-3-(4-phenoxyphenyl)-1-[(3R)-1-prop-2-enoylpiperidin-3-yl]imidazo[4,5-c]pyridin-2-one Chemical group C(C=C)(=O)N1C[C@@H](CCC1)N1C(N(C=2C(=NC=CC=21)N)C1=CC=C(C=C1)OC1=CC=CC=C1)=O KOEUOFPEZFUWRF-LJQANCHMSA-N 0.000 description 2
- SEJLPXCPMNSRAM-GOSISDBHSA-N 6-amino-9-[(3r)-1-but-2-ynoylpyrrolidin-3-yl]-7-(4-phenoxyphenyl)purin-8-one Chemical group C1N(C(=O)C#CC)CC[C@H]1N1C(=O)N(C=2C=CC(OC=3C=CC=CC=3)=CC=2)C2=C(N)N=CN=C21 SEJLPXCPMNSRAM-GOSISDBHSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 102100038079 AP2-associated protein kinase 1 Human genes 0.000 description 2
- 102100029325 ATP-dependent DNA helicase PIF1 Human genes 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 101100451277 Arabidopsis thaliana HMG2 gene Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102100032306 Aurora kinase B Human genes 0.000 description 2
- 101001125884 Autographa californica nuclear polyhedrosis virus Per os infectivity factor 1 Proteins 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 102100024507 BMP-2-inducible protein kinase Human genes 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102100035793 CD83 antigen Human genes 0.000 description 2
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 2
- 101100326430 Caenorhabditis elegans bub-1 gene Proteins 0.000 description 2
- 102100033211 Centromere protein W Human genes 0.000 description 2
- 102100031219 Centrosomal protein of 55 kDa Human genes 0.000 description 2
- 101710092479 Centrosomal protein of 55 kDa Proteins 0.000 description 2
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 2
- 102000008179 Cyclin B2 Human genes 0.000 description 2
- 108010060387 Cyclin B2 Proteins 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 2
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102100037856 DALR anticodon-binding domain-containing protein 3 Human genes 0.000 description 2
- 102100029995 DNA ligase 1 Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100037980 Disks large-associated protein 5 Human genes 0.000 description 2
- 102100023272 Dual specificity mitogen-activated protein kinase kinase 5 Human genes 0.000 description 2
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 208000002460 Enteropathy-Associated T-Cell Lymphoma Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100031517 Fc receptor-like protein 1 Human genes 0.000 description 2
- 101150051800 Fcrl1 gene Proteins 0.000 description 2
- 101150032412 Fcrla gene Proteins 0.000 description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
- 101150028819 HMGR2 gene Proteins 0.000 description 2
- 102100024002 Heterogeneous nuclear ribonucleoprotein U Human genes 0.000 description 2
- 102100030673 Histone H2A.V Human genes 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 102100030234 Homeobox protein cut-like 1 Human genes 0.000 description 2
- 101000742699 Homo sapiens AP2-associated protein kinase 1 Proteins 0.000 description 2
- 101001125842 Homo sapiens ATP-dependent DNA helicase PIF1 Proteins 0.000 description 2
- 101000762370 Homo sapiens BMP-2-inducible protein kinase Proteins 0.000 description 2
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 2
- 101100007966 Homo sapiens CTDSP2 gene Proteins 0.000 description 2
- 101000944447 Homo sapiens Centromere protein W Proteins 0.000 description 2
- 101000951866 Homo sapiens DALR anticodon-binding domain-containing protein 3 Proteins 0.000 description 2
- 101000863770 Homo sapiens DNA ligase 1 Proteins 0.000 description 2
- 101000951365 Homo sapiens Disks large-associated protein 5 Proteins 0.000 description 2
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 2
- 101000903717 Homo sapiens Glycogen synthase kinase-3 alpha Proteins 0.000 description 2
- 101001047854 Homo sapiens Heterogeneous nuclear ribonucleoprotein U Proteins 0.000 description 2
- 101001084711 Homo sapiens Histone H2A.V Proteins 0.000 description 2
- 101000726740 Homo sapiens Homeobox protein cut-like 1 Proteins 0.000 description 2
- 101000711455 Homo sapiens Kinetochore protein Spc25 Proteins 0.000 description 2
- 101001014572 Homo sapiens MARCKS-related protein Proteins 0.000 description 2
- 101001112224 Homo sapiens Neutrophil cytosol factor 2 Proteins 0.000 description 2
- 101000866805 Homo sapiens Non-histone chromosomal protein HMG-17 Proteins 0.000 description 2
- 101000602926 Homo sapiens Nuclear receptor coactivator 1 Proteins 0.000 description 2
- 101001071236 Homo sapiens PHD finger protein 19 Proteins 0.000 description 2
- 101000833892 Homo sapiens Peroxisomal acyl-coenzyme A oxidase 1 Proteins 0.000 description 2
- 101000761460 Homo sapiens Protein CASP Proteins 0.000 description 2
- 101000709305 Homo sapiens Replication protein A 14 kDa subunit Proteins 0.000 description 2
- 101001087372 Homo sapiens Securin Proteins 0.000 description 2
- 101000628647 Homo sapiens Serine/threonine-protein kinase 24 Proteins 0.000 description 2
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 description 2
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 2
- 101000687654 Homo sapiens Sorting nexin-20 Proteins 0.000 description 2
- 101000891084 Homo sapiens T-cell activation Rho GTPase-activating protein Proteins 0.000 description 2
- 101001054878 Homo sapiens Tyrosine-protein kinase Lyn Proteins 0.000 description 2
- 101000910942 Homo sapiens Uncharacterized protein C2orf81 Proteins 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 101000915604 Homo sapiens Zinc finger protein 782 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 108010068305 MAP Kinase Kinase 5 Proteins 0.000 description 2
- 102100032514 MARCKS-related protein Human genes 0.000 description 2
- 102100026240 Major facilitator superfamily domain-containing protein 3 Human genes 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 101710151814 NUAK family SNF1-like kinase 1 Proteins 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 102100023618 Neutrophil cytosol factor 2 Human genes 0.000 description 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 2
- 102100031346 Non-histone chromosomal protein HMG-17 Human genes 0.000 description 2
- 102100037223 Nuclear receptor coactivator 1 Human genes 0.000 description 2
- 102100036870 PHD finger protein 19 Human genes 0.000 description 2
- 102100026798 Peroxisomal acyl-coenzyme A oxidase 1 Human genes 0.000 description 2
- 108010001441 Phosphopeptides Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108010000598 Polycomb Repressive Complex 1 Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 102100033947 Protein regulator of cytokinesis 1 Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100034372 Replication protein A 14 kDa subunit Human genes 0.000 description 2
- 108091006572 SLC33A2 Proteins 0.000 description 2
- 102100033004 Securin Human genes 0.000 description 2
- 102100026764 Serine/threonine-protein kinase 24 Human genes 0.000 description 2
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 2
- 102100039987 Serine/threonine-protein kinase ULK2 Human genes 0.000 description 2
- 208000009359 Sezary Syndrome Diseases 0.000 description 2
- 208000021388 Sezary disease Diseases 0.000 description 2
- 102100023776 Signal peptidase complex subunit 2 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100024801 Sorting nexin-20 Human genes 0.000 description 2
- 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 102100040346 T-cell activation Rho GTPase-activating protein Human genes 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102100026857 Tyrosine-protein kinase Lyn Human genes 0.000 description 2
- 102100026672 Uncharacterized protein C2orf81 Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 102100028584 Zinc finger protein 782 Human genes 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 239000003911 antiadherent Substances 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002216 antistatic agent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- ABSXPNGWJFAPRT-UHFFFAOYSA-N benzenesulfonic acid;n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical group OS(=O)(=O)C1=CC=CC=C1.C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 ABSXPNGWJFAPRT-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 2
- 230000018486 cell cycle phase Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 238000011254 conventional chemotherapy Methods 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000003831 deregulation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940079360 enema for constipation Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000010201 enrichment analysis Methods 0.000 description 2
- QUIWHXQETADMGN-UHFFFAOYSA-N evobrutinib Chemical group C=1C=C(OC=2C=CC=CC=2)C=CC=1C=1C(N)=NC=NC=1NCC1CCN(C(=O)C=C)CC1 QUIWHXQETADMGN-UHFFFAOYSA-N 0.000 description 2
- 229950003411 evobrutinib Drugs 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 229950009618 fenebrutinib Drugs 0.000 description 2
- 229940056319 ferrosoferric oxide Drugs 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229960002258 fulvestrant Drugs 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 125000000262 haloalkenyl group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000000232 haloalkynyl group Chemical group 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000011396 initial chemotherapy Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical group C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000006070 nanosuspension Substances 0.000 description 2
- 201000006039 nodal marginal zone lymphoma Diseases 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003087 receptor blocking agent Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229940125944 selective estrogen receptor degrader Drugs 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 229950002089 spebrutinib Drugs 0.000 description 2
- 238000005563 spheronization Methods 0.000 description 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 229950009104 tirabrutinib Drugs 0.000 description 2
- 229940073613 tolebrutinib Drugs 0.000 description 2
- 239000012443 tonicity enhancing agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 229950007127 trilaciclib Drugs 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 230000009452 underexpressoin Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- STUWGJZDJHPWGZ-LBPRGKRZSA-N (2S)-N1-[4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)-4-pyridinyl]-2-thiazolyl]pyrrolidine-1,2-dicarboxamide Chemical compound S1C(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C(C)N=C1NC(=O)N1CCC[C@H]1C(N)=O STUWGJZDJHPWGZ-LBPRGKRZSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- 102100021403 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing], mitochondrial Human genes 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- IKOCUOZSKMSIPP-UHFFFAOYSA-N 2-(2-ethylpiperazin-1-yl)ethanesulfonic acid Chemical compound CCC1CNCCN1CCS(O)(=O)=O IKOCUOZSKMSIPP-UHFFFAOYSA-N 0.000 description 1
- ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical group C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 1
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 1
- 102100039822 39S ribosomal protein L55, mitochondrial Human genes 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical group FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 description 1
- 125000004861 4-isopropyl phenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 1
- 102100022984 AP-2 complex subunit alpha-1 Human genes 0.000 description 1
- 102100031315 AP-2 complex subunit mu Human genes 0.000 description 1
- 102100037651 AP-2 complex subunit sigma Human genes 0.000 description 1
- 102100021222 ATP-dependent Clp protease proteolytic subunit, mitochondrial Human genes 0.000 description 1
- 102100030088 ATP-dependent RNA helicase A Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102100033408 Acidic leucine-rich nuclear phosphoprotein 32 family member B Human genes 0.000 description 1
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 102100040277 Acyl-protein thioesterase 2 Human genes 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 1
- 102100040026 Agrin Human genes 0.000 description 1
- 102100021761 Alpha-mannosidase 2 Human genes 0.000 description 1
- 102100021954 Alpha-tubulin N-acetyltransferase 1 Human genes 0.000 description 1
- 102100040038 Amyloid beta precursor like protein 2 Human genes 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102000004000 Aurora Kinase A Human genes 0.000 description 1
- 108090000461 Aurora Kinase A Proteins 0.000 description 1
- 108090000749 Aurora kinase B Proteins 0.000 description 1
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100029648 Beta-arrestin-2 Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102100035754 Biorientation of chromosomes in cell division protein 1-like 1 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102100025351 C-type mannose receptor 2 Human genes 0.000 description 1
- 229910014585 C2-Ce Inorganic materials 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 108700015925 CELF1 Proteins 0.000 description 1
- 101150107790 CELF1 gene Proteins 0.000 description 1
- 201000004085 CLL/SLL Diseases 0.000 description 1
- 101150110330 CRAT gene Proteins 0.000 description 1
- 102100033676 CUGBP Elav-like family member 1 Human genes 0.000 description 1
- 101000864076 Caenorhabditis elegans Smu-1 suppressor of mec-8 and unc-52 protein Proteins 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100033086 Calcium/calmodulin-dependent protein kinase type 1 Human genes 0.000 description 1
- 102100025228 Calcium/calmodulin-dependent protein kinase type II subunit delta Human genes 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 101710134389 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2 Proteins 0.000 description 1
- 102100026679 Carboxypeptidase Q Human genes 0.000 description 1
- 102100036357 Carnitine O-acetyltransferase Human genes 0.000 description 1
- 102100040753 Casein kinase II subunit alpha' Human genes 0.000 description 1
- 102100032230 Caveolae-associated protein 1 Human genes 0.000 description 1
- 102100024937 Caveolae-associated protein 3 Human genes 0.000 description 1
- 102100027835 Cell death regulator Aven Human genes 0.000 description 1
- 102100032860 Cell division cycle 5-like protein Human genes 0.000 description 1
- 102100035401 Ceramide synthase 2 Human genes 0.000 description 1
- 150000000703 Cerium Chemical class 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 101150087263 Cers2 gene Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 102100032918 Chromobox protein homolog 5 Human genes 0.000 description 1
- 102100022256 Clustered mitochondria protein homolog Human genes 0.000 description 1
- 102100029136 Collagen alpha-1(II) chain Human genes 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100028250 Conserved oligomeric Golgi complex subunit 8 Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 102100039683 Cyclin-G-associated kinase Human genes 0.000 description 1
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 description 1
- 102100033245 Cyclin-dependent kinase 16 Human genes 0.000 description 1
- 102100033234 Cyclin-dependent kinase 17 Human genes 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- 102100026897 Cystatin-C Human genes 0.000 description 1
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100034109 DnaJ homolog subfamily C member 13 Human genes 0.000 description 1
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 102100036109 Dual specificity protein kinase TTK Human genes 0.000 description 1
- 102100033209 Dysbindin domain-containing protein 2 Human genes 0.000 description 1
- 108700015856 ELAV-Like Protein 1 Proteins 0.000 description 1
- 102100034235 ELAV-like protein 1 Human genes 0.000 description 1
- 101150076616 EPHA2 gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101150011861 Elavl1 gene Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102100029112 Endothelin-converting enzyme 1 Human genes 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100039735 Eukaryotic translation initiation factor 4 gamma 1 Human genes 0.000 description 1
- 102100036763 Extended synaptotagmin-1 Human genes 0.000 description 1
- 102100037583 FAST kinase domain-containing protein 5, mitochondrial Human genes 0.000 description 1
- 102100036113 Far upstream element-binding protein 3 Human genes 0.000 description 1
- 102100021056 Ferroptosis suppressor protein 1 Human genes 0.000 description 1
- 102100026149 Fibroblast growth factor receptor-like 1 Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100035130 Forkhead box protein K1 Human genes 0.000 description 1
- 101710185062 GSK3-beta interaction protein Proteins 0.000 description 1
- 102100038107 GSK3B-interacting protein Human genes 0.000 description 1
- 101710149581 GSK3B-interacting protein Proteins 0.000 description 1
- 102100030916 Gamma-soluble NSF attachment protein Human genes 0.000 description 1
- 102100033840 General transcription factor IIF subunit 1 Human genes 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100032489 Heat shock 70 kDa protein 13 Human genes 0.000 description 1
- 102100023434 Heterogeneous nuclear ribonucleoprotein A0 Human genes 0.000 description 1
- 102100035621 Heterogeneous nuclear ribonucleoprotein A1 Human genes 0.000 description 1
- 102100035669 Heterogeneous nuclear ribonucleoprotein A3 Human genes 0.000 description 1
- 102100028818 Heterogeneous nuclear ribonucleoprotein L Human genes 0.000 description 1
- 102100028896 Heterogeneous nuclear ribonucleoprotein Q Human genes 0.000 description 1
- 102100023999 Heterogeneous nuclear ribonucleoprotein R Human genes 0.000 description 1
- 102100033999 Heterogeneous nuclear ribonucleoprotein U-like protein 2 Human genes 0.000 description 1
- 102100033994 Heterogeneous nuclear ribonucleoproteins C1/C2 Human genes 0.000 description 1
- 102100030509 Histidine protein methyltransferase 1 homolog Human genes 0.000 description 1
- 102100035864 Histone lysine demethylase PHF8 Human genes 0.000 description 1
- 102100023605 Homer protein homolog 2 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001041661 Homo sapiens 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing], mitochondrial Proteins 0.000 description 1
- 101000670146 Homo sapiens 3-ketoacyl-CoA thiolase, peroxisomal Proteins 0.000 description 1
- 101000667530 Homo sapiens 39S ribosomal protein L55, mitochondrial Proteins 0.000 description 1
- 101000757299 Homo sapiens AP-2 complex subunit alpha-1 Proteins 0.000 description 1
- 101000796047 Homo sapiens AP-2 complex subunit mu Proteins 0.000 description 1
- 101000806914 Homo sapiens AP-2 complex subunit sigma Proteins 0.000 description 1
- 101000750222 Homo sapiens ATP-dependent Clp protease proteolytic subunit, mitochondrial Proteins 0.000 description 1
- 101000864670 Homo sapiens ATP-dependent RNA helicase A Proteins 0.000 description 1
- 101000732653 Homo sapiens Acidic leucine-rich nuclear phosphoprotein 32 family member B Proteins 0.000 description 1
- 101001038521 Homo sapiens Acyl-protein thioesterase 2 Proteins 0.000 description 1
- 101000959594 Homo sapiens Agrin Proteins 0.000 description 1
- 101000615953 Homo sapiens Alpha-mannosidase 2 Proteins 0.000 description 1
- 101000753184 Homo sapiens Alpha-tubulin N-acetyltransferase 1 Proteins 0.000 description 1
- 101000890401 Homo sapiens Amyloid beta precursor like protein 2 Proteins 0.000 description 1
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 1
- 101001000001 Homo sapiens Basement membrane-specific heparan sulfate proteoglycan core protein Proteins 0.000 description 1
- 101000874052 Homo sapiens Biorientation of chromosomes in cell division protein 1-like 1 Proteins 0.000 description 1
- 101000576898 Homo sapiens C-type mannose receptor 2 Proteins 0.000 description 1
- 101000944250 Homo sapiens Calcium/calmodulin-dependent protein kinase type 1 Proteins 0.000 description 1
- 101001077338 Homo sapiens Calcium/calmodulin-dependent protein kinase type II subunit delta Proteins 0.000 description 1
- 101000868788 Homo sapiens Carboxypeptidase D Proteins 0.000 description 1
- 101000910846 Homo sapiens Carboxypeptidase Q Proteins 0.000 description 1
- 101000892015 Homo sapiens Casein kinase II subunit alpha' Proteins 0.000 description 1
- 101000869049 Homo sapiens Caveolae-associated protein 1 Proteins 0.000 description 1
- 101000761506 Homo sapiens Caveolae-associated protein 3 Proteins 0.000 description 1
- 101000698131 Homo sapiens Cell death regulator Aven Proteins 0.000 description 1
- 101000868318 Homo sapiens Cell division cycle 5-like protein Proteins 0.000 description 1
- 101000797581 Homo sapiens Chromobox protein homolog 5 Proteins 0.000 description 1
- 101000902167 Homo sapiens Clustered mitochondria protein homolog Proteins 0.000 description 1
- 101000771163 Homo sapiens Collagen alpha-1(II) chain Proteins 0.000 description 1
- 101000860644 Homo sapiens Conserved oligomeric Golgi complex subunit 8 Proteins 0.000 description 1
- 101000886209 Homo sapiens Cyclin-G-associated kinase Proteins 0.000 description 1
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 description 1
- 101000944357 Homo sapiens Cyclin-dependent kinase 16 Proteins 0.000 description 1
- 101000944358 Homo sapiens Cyclin-dependent kinase 17 Proteins 0.000 description 1
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 101000912205 Homo sapiens Cystatin-C Proteins 0.000 description 1
- 101000919466 Homo sapiens Cytochrome c oxidase subunit 7A-related protein, mitochondrial Proteins 0.000 description 1
- 101000870239 Homo sapiens DnaJ homolog subfamily C member 13 Proteins 0.000 description 1
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 1
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 description 1
- 101000871249 Homo sapiens Dysbindin domain-containing protein 2 Proteins 0.000 description 1
- 101001107084 Homo sapiens E3 ubiquitin-protein ligase RNF5 Proteins 0.000 description 1
- 101000841259 Homo sapiens Endothelin-converting enzyme 1 Proteins 0.000 description 1
- 101001034825 Homo sapiens Eukaryotic translation initiation factor 4 gamma 1 Proteins 0.000 description 1
- 101000851525 Homo sapiens Extended synaptotagmin-1 Proteins 0.000 description 1
- 101001028241 Homo sapiens FAST kinase domain-containing protein 5, mitochondrial Proteins 0.000 description 1
- 101000930753 Homo sapiens Far upstream element-binding protein 3 Proteins 0.000 description 1
- 101000818014 Homo sapiens Ferroptosis suppressor protein 1 Proteins 0.000 description 1
- 101000912518 Homo sapiens Fibroblast growth factor receptor-like 1 Proteins 0.000 description 1
- 101001023398 Homo sapiens Forkhead box protein K1 Proteins 0.000 description 1
- 101000702693 Homo sapiens Gamma-soluble NSF attachment protein Proteins 0.000 description 1
- 101000640758 Homo sapiens General transcription factor IIF subunit 1 Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101001016638 Homo sapiens Heat shock 70 kDa protein 13 Proteins 0.000 description 1
- 101000685879 Homo sapiens Heterogeneous nuclear ribonucleoprotein A0 Proteins 0.000 description 1
- 101000854014 Homo sapiens Heterogeneous nuclear ribonucleoprotein A1 Proteins 0.000 description 1
- 101000854041 Homo sapiens Heterogeneous nuclear ribonucleoprotein A3 Proteins 0.000 description 1
- 101000839078 Homo sapiens Heterogeneous nuclear ribonucleoprotein L Proteins 0.000 description 1
- 101000839069 Homo sapiens Heterogeneous nuclear ribonucleoprotein Q Proteins 0.000 description 1
- 101001047853 Homo sapiens Heterogeneous nuclear ribonucleoprotein R Proteins 0.000 description 1
- 101001017570 Homo sapiens Heterogeneous nuclear ribonucleoprotein U-like protein 2 Proteins 0.000 description 1
- 101001017574 Homo sapiens Heterogeneous nuclear ribonucleoproteins C1/C2 Proteins 0.000 description 1
- 101000990524 Homo sapiens Histidine protein methyltransferase 1 homolog Proteins 0.000 description 1
- 101001000378 Homo sapiens Histone lysine demethylase PHF8 Proteins 0.000 description 1
- 101001048464 Homo sapiens Homer protein homolog 2 Proteins 0.000 description 1
- 101000960484 Homo sapiens Inner centromere protein Proteins 0.000 description 1
- 101000840572 Homo sapiens Insulin-like growth factor-binding protein 4 Proteins 0.000 description 1
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 1
- 101001044438 Homo sapiens Intraflagellar transport protein 52 homolog Proteins 0.000 description 1
- 101000975528 Homo sapiens Junction-mediating and -regulatory protein Proteins 0.000 description 1
- 101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 description 1
- 101001008527 Homo sapiens Laminin subunit alpha-5 Proteins 0.000 description 1
- 101001054649 Homo sapiens Latent-transforming growth factor beta-binding protein 2 Proteins 0.000 description 1
- 101001054646 Homo sapiens Latent-transforming growth factor beta-binding protein 3 Proteins 0.000 description 1
- 101000966742 Homo sapiens Leucine-rich PPR motif-containing protein, mitochondrial Proteins 0.000 description 1
- 101000941892 Homo sapiens Leucine-rich repeat and calponin homology domain-containing protein 4 Proteins 0.000 description 1
- 101000579789 Homo sapiens Leucine-rich repeat-containing protein 59 Proteins 0.000 description 1
- 101000764294 Homo sapiens Lymphotoxin-beta Proteins 0.000 description 1
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 1
- 101001115417 Homo sapiens M-phase phosphoprotein 8 Proteins 0.000 description 1
- 101001057234 Homo sapiens MAM domain-containing protein 2 Proteins 0.000 description 1
- 101001052384 Homo sapiens MICAL-like protein 2 Proteins 0.000 description 1
- 101000950648 Homo sapiens Malectin Proteins 0.000 description 1
- 101000957559 Homo sapiens Matrin-3 Proteins 0.000 description 1
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 1
- 101001132841 Homo sapiens Mitochondrial ribosome-associated GTPase 1 Proteins 0.000 description 1
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 1
- 101001018157 Homo sapiens Mitogen-activated protein kinase kinase kinase 20 Proteins 0.000 description 1
- 101000886220 Homo sapiens N-acetylgalactosaminyltransferase 7 Proteins 0.000 description 1
- 101000624956 Homo sapiens Nesprin-2 Proteins 0.000 description 1
- 101000912678 Homo sapiens Nucleolar RNA helicase 2 Proteins 0.000 description 1
- 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 description 1
- 101000974015 Homo sapiens Nucleosome assembly protein 1-like 1 Proteins 0.000 description 1
- 101001082142 Homo sapiens Pentraxin-related protein PTX3 Proteins 0.000 description 1
- 101000878221 Homo sapiens Peptidyl-prolyl cis-trans isomerase FKBP8 Proteins 0.000 description 1
- 101000601274 Homo sapiens Period circadian protein homolog 3 Proteins 0.000 description 1
- 101000605630 Homo sapiens Phosphatidylinositol 3-kinase catalytic subunit type 3 Proteins 0.000 description 1
- 101001001531 Homo sapiens Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha Proteins 0.000 description 1
- 101001001527 Homo sapiens Phosphatidylinositol 5-phosphate 4-kinase type-2 beta Proteins 0.000 description 1
- 101000692672 Homo sapiens Phosphoinositide 3-kinase regulatory subunit 4 Proteins 0.000 description 1
- 101000829538 Homo sapiens Polypeptide N-acetylgalactosaminyltransferase 15 Proteins 0.000 description 1
- 101000914035 Homo sapiens Pre-mRNA-splicing regulator WTAP Proteins 0.000 description 1
- 101000917550 Homo sapiens Probable fibrosin-1 Proteins 0.000 description 1
- 101000869861 Homo sapiens Protein DGCR6 Proteins 0.000 description 1
- 101000881752 Homo sapiens Protein ELYS Proteins 0.000 description 1
- 101000931462 Homo sapiens Protein FosB Proteins 0.000 description 1
- 101000861454 Homo sapiens Protein c-Fos Proteins 0.000 description 1
- 101001086519 Homo sapiens Pseudouridylate synthase 7 homolog-like protein Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101001048695 Homo sapiens RNA polymerase II elongation factor ELL Proteins 0.000 description 1
- 101001089098 Homo sapiens RNA polymerase-associated protein LEO1 Proteins 0.000 description 1
- 101001076728 Homo sapiens RNA-binding protein 34 Proteins 0.000 description 1
- 101000619506 Homo sapiens Ragulator complex protein LAMTOR2 Proteins 0.000 description 1
- 101000686227 Homo sapiens Ras-related protein R-Ras2 Proteins 0.000 description 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 101000727979 Homo sapiens Remodeling and spacing factor 1 Proteins 0.000 description 1
- 101001104307 Homo sapiens Ribonuclease 7 Proteins 0.000 description 1
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 description 1
- 101000863815 Homo sapiens SHC SH2 domain-binding protein 1 Proteins 0.000 description 1
- 101000652133 Homo sapiens STE20-like serine/threonine-protein kinase Proteins 0.000 description 1
- 101000648174 Homo sapiens Serine/threonine-protein kinase 10 Proteins 0.000 description 1
- 101000661821 Homo sapiens Serine/threonine-protein kinase 17A Proteins 0.000 description 1
- 101000661819 Homo sapiens Serine/threonine-protein kinase 17B Proteins 0.000 description 1
- 101000771237 Homo sapiens Serine/threonine-protein kinase A-Raf Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101001026870 Homo sapiens Serine/threonine-protein kinase D1 Proteins 0.000 description 1
- 101001047642 Homo sapiens Serine/threonine-protein kinase LATS1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000576904 Homo sapiens Serine/threonine-protein kinase MRCK beta Proteins 0.000 description 1
- 101000577652 Homo sapiens Serine/threonine-protein kinase PRP4 homolog Proteins 0.000 description 1
- 101000709250 Homo sapiens Serine/threonine-protein kinase SIK2 Proteins 0.000 description 1
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 description 1
- 101000607332 Homo sapiens Serine/threonine-protein kinase ULK2 Proteins 0.000 description 1
- 101000637839 Homo sapiens Serine/threonine-protein kinase tousled-like 1 Proteins 0.000 description 1
- 101000824952 Homo sapiens Sorting nexin-30 Proteins 0.000 description 1
- 101000824920 Homo sapiens Sorting nexin-33 Proteins 0.000 description 1
- 101000665025 Homo sapiens Sorting nexin-6 Proteins 0.000 description 1
- 101000703512 Homo sapiens Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
- 101000651021 Homo sapiens Splicing factor, arginine/serine-rich 19 Proteins 0.000 description 1
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- 101000617805 Homo sapiens Staphylococcal nuclease domain-containing protein 1 Proteins 0.000 description 1
- 101000697810 Homo sapiens Syntaxin-5 Proteins 0.000 description 1
- 101001099181 Homo sapiens TATA-binding protein-associated factor 2N Proteins 0.000 description 1
- 101000801195 Homo sapiens TLE family member 5 Proteins 0.000 description 1
- 101000851850 Homo sapiens Trafficking protein particle complex subunit 14 Proteins 0.000 description 1
- 101000837841 Homo sapiens Transcription factor EB Proteins 0.000 description 1
- 101001068204 Homo sapiens Type 2 phosphatidylinositol 4,5-bisphosphate 4-phosphatase Proteins 0.000 description 1
- 101000864342 Homo sapiens Tyrosine-protein kinase BTK Proteins 0.000 description 1
- 101001022129 Homo sapiens Tyrosine-protein kinase Fyn Proteins 0.000 description 1
- 101001009087 Homo sapiens Tyrosine-protein kinase HCK Proteins 0.000 description 1
- 101000820294 Homo sapiens Tyrosine-protein kinase Yes Proteins 0.000 description 1
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 1
- 101000749407 Homo sapiens UV-stimulated scaffold protein A Proteins 0.000 description 1
- 101000671649 Homo sapiens Upstream stimulatory factor 2 Proteins 0.000 description 1
- 101000984121 Homo sapiens Vesicular integral-membrane protein VIP36 Proteins 0.000 description 1
- 101000864104 Homo sapiens WD40 repeat-containing protein SMU1 Proteins 0.000 description 1
- 101000976569 Homo sapiens Zinc finger CCHC-type and RNA-binding motif-containing protein 1 Proteins 0.000 description 1
- 101000759174 Homo sapiens Zinc finger RNA-binding protein Proteins 0.000 description 1
- 101000818783 Homo sapiens Zinc finger protein 260 Proteins 0.000 description 1
- 101000818832 Homo sapiens Zinc finger protein 608 Proteins 0.000 description 1
- 101000620751 Homo sapiens mRNA export factor RAE1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100039872 Inner centromere protein Human genes 0.000 description 1
- 102100029224 Insulin-like growth factor-binding protein 4 Human genes 0.000 description 1
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102100022470 Intraflagellar transport protein 52 homolog Human genes 0.000 description 1
- 102100023956 Junction-mediating and -regulatory protein Human genes 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 102100026023 LIM domain kinase 1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100027450 Laminin subunit alpha-5 Human genes 0.000 description 1
- 102100034710 Laminin subunit gamma-1 Human genes 0.000 description 1
- 102100027017 Latent-transforming growth factor beta-binding protein 2 Human genes 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 102100040589 Leucine-rich PPR motif-containing protein, mitochondrial Human genes 0.000 description 1
- 102100032680 Leucine-rich repeat and calponin homology domain-containing protein 4 Human genes 0.000 description 1
- 102100028206 Leucine-rich repeat-containing protein 59 Human genes 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100026894 Lymphotoxin-beta Human genes 0.000 description 1
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 1
- 102100023268 M-phase phosphoprotein 8 Human genes 0.000 description 1
- 102100027237 MAM domain-containing protein 2 Human genes 0.000 description 1
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 description 1
- 102100024307 MICAL-like protein 2 Human genes 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 102100037750 Malectin Human genes 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical group O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102100038645 Matrin-3 Human genes 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100033815 Mitochondrial ribosome-associated GTPase 1 Human genes 0.000 description 1
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 1
- 102100033116 Mitogen-activated protein kinase kinase kinase 20 Human genes 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- PBJMYYWFAJGFCX-UHFFFAOYSA-N N#Cc1cccc(c1)-c1cc2c(Nc3ccncc3)ncnn2c1 Chemical compound N#Cc1cccc(c1)-c1cc2c(Nc3ccncc3)ncnn2c1 PBJMYYWFAJGFCX-UHFFFAOYSA-N 0.000 description 1
- UKBGBACORPRCGG-UHFFFAOYSA-N N-[3-[[5-cyclopropyl-2-[3-(4-morpholinylmethyl)anilino]-4-pyrimidinyl]amino]propyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NCCCNC(C(=CN=1)C2CC2)=NC=1NC(C=1)=CC=CC=1CN1CCOCC1 UKBGBACORPRCGG-UHFFFAOYSA-N 0.000 description 1
- 102100023305 Nesprin-2 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
- 108010010424 Nuclear Factor 90 Proteins Proteins 0.000 description 1
- 102000015863 Nuclear Factor 90 Proteins Human genes 0.000 description 1
- 102100022678 Nucleophosmin Human genes 0.000 description 1
- 102100022389 Nucleosome assembly protein 1-like 1 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BFHAYPLBUQVNNJ-UHFFFAOYSA-N Pectenotoxin 3 Natural products OC1C(C)CCOC1(O)C1OC2C=CC(C)=CC(C)CC(C)(O3)CCC3C(O3)(O4)CCC3(C=O)CC4C(O3)C(=O)CC3(C)C(O)C(O3)CCC3(O3)CCCC3C(C)C(=O)OC2C1 BFHAYPLBUQVNNJ-UHFFFAOYSA-N 0.000 description 1
- 102100027351 Pentraxin-related protein PTX3 Human genes 0.000 description 1
- 102100036978 Peptidyl-prolyl cis-trans isomerase FKBP8 Human genes 0.000 description 1
- 102100037630 Period circadian protein homolog 3 Human genes 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 102100038329 Phosphatidylinositol 3-kinase catalytic subunit type 3 Human genes 0.000 description 1
- 102100036146 Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha Human genes 0.000 description 1
- 102100036137 Phosphatidylinositol 5-phosphate 4-kinase type-2 beta Human genes 0.000 description 1
- 102100026481 Phosphoinositide 3-kinase regulatory subunit 4 Human genes 0.000 description 1
- 102100023229 Polypeptide N-acetylgalactosaminyltransferase 15 Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000000434 Pre-B Cell Receptors Human genes 0.000 description 1
- 108010016231 Pre-B Cell Receptors Proteins 0.000 description 1
- 102100026431 Pre-mRNA-splicing regulator WTAP Human genes 0.000 description 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 1
- 102100037427 Probable ATP-dependent RNA helicase DDX56 Human genes 0.000 description 1
- 102100029532 Probable fibrosin-1 Human genes 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102100032505 Protein DGCR6 Human genes 0.000 description 1
- 102100037113 Protein ELYS Human genes 0.000 description 1
- 102100020847 Protein FosB Human genes 0.000 description 1
- 108010003506 Protein Kinase D2 Proteins 0.000 description 1
- 102100027584 Protein c-Fos Human genes 0.000 description 1
- 102100023068 Protein kinase C-binding protein NELL1 Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100032779 Pseudouridylate synthase 7 homolog-like protein Human genes 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- 102100023449 RNA polymerase II elongation factor ELL Human genes 0.000 description 1
- 102100033754 RNA polymerase-associated protein LEO1 Human genes 0.000 description 1
- 102100025870 RNA-binding protein 34 Human genes 0.000 description 1
- 102000056817 RNF5 Human genes 0.000 description 1
- 102100022154 Ragulator complex protein LAMTOR2 Human genes 0.000 description 1
- 102100025003 Ras-related protein R-Ras2 Human genes 0.000 description 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 206010070308 Refractory cancer Diseases 0.000 description 1
- 102100029771 Remodeling and spacing factor 1 Human genes 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 description 1
- 102100029989 SHC SH2 domain-binding protein 1 Human genes 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 102100030571 STE20-like serine/threonine-protein kinase Human genes 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 102100028900 Serine/threonine-protein kinase 10 Human genes 0.000 description 1
- 102100037955 Serine/threonine-protein kinase 17A Human genes 0.000 description 1
- 102100037959 Serine/threonine-protein kinase 17B Human genes 0.000 description 1
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 description 1
- 102100037312 Serine/threonine-protein kinase D2 Human genes 0.000 description 1
- 102100024031 Serine/threonine-protein kinase LATS1 Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100025347 Serine/threonine-protein kinase MRCK beta Human genes 0.000 description 1
- 102100028868 Serine/threonine-protein kinase PRP4 homolog Human genes 0.000 description 1
- 102100034377 Serine/threonine-protein kinase SIK2 Human genes 0.000 description 1
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 description 1
- 101710203717 Serine/threonine-protein kinase ULK2 Proteins 0.000 description 1
- 102100032015 Serine/threonine-protein kinase tousled-like 1 Human genes 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102100022382 Sorting nexin-33 Human genes 0.000 description 1
- 102100038626 Sorting nexin-6 Human genes 0.000 description 1
- 102100030684 Sphingosine-1-phosphate phosphatase 1 Human genes 0.000 description 1
- 102100027779 Splicing factor, arginine/serine-rich 19 Human genes 0.000 description 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 1
- 102100021996 Staphylococcal nuclease domain-containing protein 1 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100027973 Syntaxin-5 Human genes 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100038917 TATA-binding protein-associated factor 2N Human genes 0.000 description 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
- 102100033766 TLE family member 5 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102100036478 Trafficking protein particle complex subunit 14 Human genes 0.000 description 1
- 102100028502 Transcription factor EB Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- 102100034495 Type 2 phosphatidylinositol 4,5-bisphosphate 4-phosphatase Human genes 0.000 description 1
- 102100027389 Tyrosine-protein kinase HCK Human genes 0.000 description 1
- 102100021788 Tyrosine-protein kinase Yes Human genes 0.000 description 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 1
- 102000003450 UFL1 Human genes 0.000 description 1
- 102100040533 UV-stimulated scaffold protein A Human genes 0.000 description 1
- 102100040103 Upstream stimulatory factor 2 Human genes 0.000 description 1
- 102100025455 Vesicular integral-membrane protein VIP36 Human genes 0.000 description 1
- 102100029872 WD40 repeat-containing protein SMU1 Human genes 0.000 description 1
- 101100445056 Xenopus laevis elavl1-a gene Proteins 0.000 description 1
- 101100445057 Xenopus laevis elavl1-b gene Proteins 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102100023585 Zinc finger CCHC-type and RNA-binding motif-containing protein 1 Human genes 0.000 description 1
- 102100023406 Zinc finger RNA-binding protein Human genes 0.000 description 1
- 102100021360 Zinc finger protein 260 Human genes 0.000 description 1
- 102100021354 Zinc finger protein 608 Human genes 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 229950010482 alpelisib Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000004908 autophagic flux Effects 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 208000003373 basosquamous carcinoma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 108010032967 beta-Arrestin 2 Proteins 0.000 description 1
- BVCRERJDOOBZOH-UHFFFAOYSA-N bicyclo[2.2.1]heptanyl Chemical group C1C[C+]2CC[C-]1C2 BVCRERJDOOBZOH-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical group NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001661 cadmium Chemical class 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- ZMIGMASIKSOYAM-UHFFFAOYSA-N cerium Chemical compound [Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce][Ce] ZMIGMASIKSOYAM-UHFFFAOYSA-N 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 150000001868 cobalt Chemical class 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229950002550 copanlisib Drugs 0.000 description 1
- PZBCKZWLPGJMAO-UHFFFAOYSA-N copanlisib Chemical compound C1=CC=2C3=NCCN3C(NC(=O)C=3C=NC(N)=NC=3)=NC=2C(OC)=C1OCCCN1CCOCC1 PZBCKZWLPGJMAO-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229950004949 duvelisib Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229940125641 estrogen receptor degrader Drugs 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000021173 high grade B-cell lymphoma Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000000879 imine group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 108010090909 laminin gamma 1 Proteins 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 102100022885 mRNA export factor RAE1 Human genes 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 150000002696 manganese Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- KKISLZKMBSCLSS-UHFFFAOYSA-N n-[3-[[5-cyclopropyl-2-[(2-methyl-3,4-dihydro-1h-isoquinolin-6-yl)amino]pyrimidin-4-yl]amino]propyl]cyclobutanecarboxamide Chemical compound C=1C=C2CN(C)CCC2=CC=1NC(N=C1NCCCNC(=O)C2CCC2)=NC=C1C1CC1 KKISLZKMBSCLSS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- UZGLIIJVICEWHF-UHFFFAOYSA-N octogen Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)CN([N+]([O-])=O)C1 UZGLIIJVICEWHF-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960000160 recombinant therapeutic protein Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 201000011453 reproductive organ cancer Diseases 0.000 description 1
- 208000015608 reproductive system cancer Diseases 0.000 description 1
- 230000029054 response to nutrient Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 125000000565 sulfonamide group Chemical group 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 125000003375 sulfoxide group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229930192474 thiophene Chemical group 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 150000003608 titanium Chemical class 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 101150091685 ufl1 gene Proteins 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Definitions
- Mantle cell lymphoma is an aggressive, rare form of non-Hodgkin lymphoma (NHL).
- NHL non-Hodgkin lymphoma
- a method of treating lymphoma in a human subject in need thereof comprising administering to the subject a therapeutically- effective amount of a compound of formula (I) wherein:
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen;
- R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen;
- a method of treating lymphoma in a subject in need thereof comprising administering to the subject a therapeutically- effective amount of a compound of formula (I) wherein:
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen;
- R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen;
- a method of treating lymphoma in a subject in need thereof comprising administering to the subject a therapeutically- effective amount of a compound of formula (I) wherein:
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen;
- R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen;
- a method of treating lymphoma in a subject in need thereof comprising administering to the subject a therapeutically- effective amount of a compound of formula (I) wherein:
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen;
- R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen;
- a method of treating lymphoma in a subject in need thereof comprising
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen;
- R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen;
- combination comprising:
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen;
- R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen;
- the second compound is a BTK inhibitor. In some embodiments, the second compound is ibrutinib or a pharmaceutically-acceptable salt thereof. In some embodiments, the second compound is acalabrutinib or a pharmaceutically- acceptable salt thereof.
- the compound of formula (1) 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile monolactate or a pharmaceutically-acceptable salt thereof.
- the compound of formula (I) is 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)- 7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile achieves synergistic activity in combination with ibrutinib.
- the synergistic activity is in mantle cell lymphoma cells (MCL).
- the synergistic activity is in BTK inhibitorresistant MCL cells.
- the compound of formula (1) 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile monolactate or a pharmaceutically-acceptable salt thereof.
- the compound of formula (I) is 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)- 7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile achieves synergistic activity in combination with acalabrutinib.
- the synergistic activity is in mantle cell lymphoma cells (MCL).
- MCL mantle cell lymphoma cells
- the synergistic activity is in BTK inhibitor-resistant MCL cells.
- the compound of formula (I) is 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof.
- the compound of formula (I) is 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7- oxo-7, 8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.
- a method of treating mantle cell lymphoma in a subject in need thereof comprising orally administering to the subject a solid pharmaceutical composition, the solid pharmaceutical composition comprising 40 mg to 500 mg of a compound that is 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo- 7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, wherein the subject received a therapy other than the compound for the mantle cell lymphoma prior to the administering, wherein the therapy was received after the subject was diagnosed with mantle cell lymphoma, and wherein the subject has not responded to the therapy prior to the administering; and wherein the administering is once daily for at least 3 weeks.
- a method of treating mantle cell lymphoma in a subject in need thereof comprising, (i) orally administering to the subject a solid pharmaceutical composition, wherein the solid pharmaceutical composition comprises 40 mg to 500 mg of a compound that is 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, wherein the subject received a therapy other than the compound for the mantle cell lymphoma prior to the administering, wherein the therapy was received after the subject was diagnosed with mantle cell lymphoma, and wherein the subject has not responded to the therapy prior to the administering, and wherein the administering comprises 3 weeks of once- daily administration; and (ii) orally administering to the subject a therapeutically-effective amount of ibrutinib or a pharmaceutical
- a method of treating mantle cell lymphoma in a subject in need thereof comprising, (i) orally administering to the subject a solid pharmaceutical composition, wherein the solid pharmaceutical composition comprises 40 mg to 500 mg of a compound that is 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, wherein the subject received a therapy other than the compound for the mantle cell lymphoma prior to the administering, wherein the therapy was received after the subject was diagnosed with mantle cell lymphoma, and wherein the subject has not responded to the therapy prior to the administering, and wherein the administering comprises 3 weeks of once- daily administration; and (ii) orally administering to the subject a therapeutically-effective amount of acalabrutinib or
- a method of treating Bruton tyrosine kinase inhibitor-resistant mantle cell lymphoma in a subject in need thereof comprising orally administering to the subject a solid pharmaceutical composition, the solid pharmaceutical composition comprising 40 mg to 500 mg of a compound that is 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile monolactate, wherein the subject received a therapy other than the compound for the mantle cell lymphoma prior to the administering, wherein the therapy was received after the subject was diagnosed with mantle cell lymphoma, and wherein the subject has not responded to the therapy prior to the administering; and wherein the administering is once daily for at least 3 weeks.
- a method of treating Bruton tyrosine kinase inhibitor-resistant mantle cell lymphoma in a subject in need thereof comprising, (i) orally administering to the subject a solid pharmaceutical composition, wherein the solid pharmaceutical composition comprises 40 mg to 500 mg of a compound that is 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile monolactate, wherein the subject received a therapy other than the compound for the mantle cell lymphoma prior to the administering, wherein the therapy was received after the subject was diagnosed with mantle cell lymphoma, and wherein the subject has not responded to the therapy prior to the administering, and wherein the administering comprises 3 weeks of once-daily administration; and (ii) orally administering to the
- a method of treating Bruton tyrosine kinase inhibitor-resistant mantle cell lymphoma in a subject in need thereof comprising, (i) orally administering to the subject a solid pharmaceutical composition, wherein the solid pharmaceutical composition comprises 40 mg to 500 mg of a compound that is 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile monolactate, wherein the subject received a therapy other than the compound for the mantle cell lymphoma prior to the administering, wherein the therapy was received after the subject was diagnosed with mantle cell lymphoma, and wherein the subject has not responded to the therapy prior to the administering, and wherein the administering comprises 3 weeks of once-daily administration; and (ii) orally administering to the
- FIG. 1 shows tumors treated with compound- 1 shows a greater reduction in tumor volume compared to the control.
- FIG. 2 shows mice treated with compound- 1 shows a greater reduction in tumor volume compared to the mice treated with control.
- FIG. 3 shows Western Blot analysis of MCL cell lines JEKO, UPN-1, REC-1, MINO, GRANTA-519, Z-138, and modified counterpart MCL cell lines UPN-ibrutinib resistant, REC-1 BTK mutant, and REC-1 BTK KO.
- FIG. 4 shows percentage of cell viability in MCL cell lines JEKO, UPN-1, REC-1, MINO, GRANTA-519, and Z-138, treated with increasing doses of Compound (1) for 72 hours.
- FIG. 5 shows percentage of cell viability in modified counterpart MCL cell lines UPN-ibrutinib resistant, REC-1 BTK mutant, REC-1 BTK KO, and REC-1 IKAROS KO treated with increasing doses of Compound (1) for 72 hours.
- FIG. 6 shows Combination Index (CI) from CTG proliferation assays of MCL cell lines JEKO, UPNT-1, REC-1, Z-138, REC-1 IKAROS KO, UPN-ibrutinib resistant, REC-1 BTK mutant, and REC-1 BTK KO for various doses of Compound (1) combined with ibrutinib.
- CI Combination Index
- FIG. 7 shows Combination Index (CI) from CTG proliferation assays of MCL cell lines JEKO, UPNT-1, REC-1, Z-138, REC-1 IKAROS KO, UPN-ibrutinib resistant, REC-1 BTK mutant, and REC-1 BTK KO for various doses of Compound (1) combined with acalabrutinib.
- CI Combination Index
- FIG. 8 shows a CTG proliferation assay in MCL cell line UPN-1 treated with CDK4/6 inhibitors, BTK inhibitors, and a combination of CDK4/6 inhibitors and BTK inhibitors.
- FIG. 9 shows a CTG proliferation assay in MCL cell line REC-1 treated with CDK4/6 inhibitors, BTK inhibitors, and a combination of CDK4/6 inhibitors and BTK inhibitors.
- FIG. 10 shows a CTG proliferation assay in MCL cell line JEKO-1 treated with CDK4/6 inhibitors, BTK inhibitors, and a combination of CDK4/6 inhibitors and BTK inhibitors.
- FIG. 11 shows a CTG proliferation assay in modified counterpart MCL cell line UPN-ibrutinib resistant (UPN-1 IbruR) treated with CDK4/6 inhibitors, BTK inhibitors, and a combination of CDK4/6 inhibitors and BTK inhibitors.
- UPN-1 IbruR UPN-ibrutinib resistant
- FIG. 12 shows a CTG proliferation assay in modified counterpart MCL cell line REC-1 BTK KO treated with CDK4/6 inhibitors, BTK inhibitors, and a combination of CDK4/6 inhibitors and BTK inhibitors.
- FIG. 13 shows a CTG proliferation assay in modified counterpart MCL cell line REC-1 IKAROS KO treated with CDK4/6 inhibitors, BTK inhibitors, and a combination of CDK4/6 inhibitors and BTK inhibitors.
- FIG. 14 shows cell cycle analysis in MCL cell line REC-1 treated with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 15 shows cell cycle analysis in MCL cell line Z-138 treated with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 16 shows cell cycle analysis in MCL cell line JEKO-1 treated with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 17 shows cell cycle analysis in MCL cell line UPN-1 treated with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 18 shows cell cycle analysis in modified counterpart MCL cell line UPN- ibrutinib resistant (UPN-1 IbruR) treated with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- UPN-1 IbruR UPN- ibrutinib resistant
- FIG. 19 shows cell cycle analysis in MCL cell line JEKO-1 treated with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 20 shows apoptosis analysis of MCL cell line JEKO-1 assessed by AnnexinV+ staining after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 21 shows apoptosis analysis of MCL cell line JEKO-1 assessed by AnnexinV+ staining after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 22 shows apoptosis analysis of MCL cell line Z-138 assessed by mitochondrial transmembrane potential (Aym) loss after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 23 shows apoptosis analysis of MCL cell line JEKO-1 assessed by mitochondrial transmembrane potential (Aym) loss after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 24 shows Western blot analysis of MCL cell line UPN-1 after treatment with Compound (1), BTK inhibitors, ibrutinib, acalabrutinib, or pirtobrutinib (Loxo-305), and a combination of Compound (1) with BTK inhibitors.
- FIG. 25 shows Western blot analysis of modified counterpart MCL cell line UPN- ibrutinib resistant (UPN-1 IbruR) after treatment with Compound (1), BTK inhibitors, ibrutinib, acalabrutinib, or pirtobrutinib (Loxo-305), and a combination of Compound (1) with BTK inhibitors.
- UPN-1 IbruR UPN- ibrutinib resistant
- BTK inhibitors ibrutinib
- acalabrutinib acalabrutinib
- pirtobrutinib Lixo-305
- FIG. 26 shows qRT-PCR quantification of cell -cycle related transcript AURKB in MCL cell JEKO-1 after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 27 shows qRT-PCR quantification of cell -cycle related transcript CDK1 in MCL cell JEKO-1 after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 28 shows qRT-PCR quantification of cell -cycle related transcript Cyclin B2 (CCNB2) in MCL cell JEKO-1 after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- CCNB2 cell -cycle related transcript Cyclin B2
- FIG. 29 shows qRT-PCR quantification of cell -cycle related transcript CDC20 in MCL cell JEKO-1 after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 30 shows qRT-PCR quantification of cell -cycle related transcript P16 (CDKN2A) in MCL cell JEKO-1 after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 31 shows qRT-PCR quantification of cell -cycle related transcript P27 (CDKN1B) in MCL cell JEKO-1 after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 32 shows qRT-PCR quantification of senescence related transcript IL-6 in MCL cell JEKO-1 after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 33 shows qRT-PCR quantification of senescence related transcript IL-8 in MCL cell JEKO-1 after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 34 shows qRT-PCR quantification of senescence related transcript CXCL1 in MCL cell JEKO-1 after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 35 shows qRT-PCR quantification of senescence related transcript MCP1 in MCL cell JEKO-1 after treatment with Compound (1), BTK inhibitors, and a combination of Compound (1) with BTK inhibitors.
- FIG. 36 shows a heatmap of genes differentially regulated upon treatment with Compound (1) in MCL cell lines (UPN-1, UPN-IbruR, REC-1, JEKO-1 and MINO).
- FIG. 37 shows a heatmap of genes differentially regulated upon treatment with Compound (1) in MCL cell lines (UPN-1, UPN-IbruR, REC-1, JEKO-1 and MINO).
- FIG. 38 shows comparison of gene set enrichment analysis (GSEA) and proteomics analysis of MCL cell lines (UPN-1, UPN-1 RES) following exposure to a control compound or to Compound (1).
- GSEA gene set enrichment analysis
- FIG. 39 shows GSEA for E2F targets after transcriptomic (RNAseq) characterization of MCL cell lines following exposure to Compound (1).
- FIG. 40 shows GSEA for MYC targets after transcriptomic (RNAseq) characterization of MCL cell lines following exposure to Compound (1).
- FIG. 41 shows GSEA for G2/M checkpoints after transcriptomic (RNAseq) characterization of MCL cell lines following exposure to Compound (1).
- FIG. 42 shows GSEA for DNA repair after transcriptomic (RNAseq) characterization of MCL cell lines following exposure to Compound (1).
- FIG. 43 shows GSEA for TNFa signaling via NFKB after transcriptomic (RNAseq) characterization of MCL cell lines following exposure to Compound (1).
- FIG. 44 shows GSEA for inflammatory response after transcriptomic (RNAseq) characterization of MCL cell lines following exposure to Compound (1).
- FIG. 45 shows a schematic timeline for the chorioallantoic membrane chick embryo (CAM) model.
- FIG. 46 shows egg weights of eggs inoculated with UPN-1 cells treated twice by CDK4/6 inhibitor or a combination of CDK4/6 inhibitor with ibrutinib.
- FIG. 47 shows egg weights of eggs inoculated with UPN-IbruR cells treated twice by CDK4/6 inhibitor or a combination of CDK4/6 inhibitor with ibrutinib.
- FIG. 48 shows embryo weights at day 7 after inoculation after treatment with CDK4/6 inhibitor or a combination of CDK4/6 inhibitor with ibrutinib.
- FIG. 49 shows tumor weights at day 7 after inoculation with JEKO-1 cells and treatment with CDK4/6 inhibitor, BTK inhibitor ibrutinib, or a combination of CDK4/6 inhibitor with ibrutinib.
- FIG. 50 shows tumor weights at day 7 after inoculation with UPN-1 cells and treatment with CDK4/6 inhibitor, BTK inhibitor ibrutinib or a combination of CDK4/6 inhibitor with ibrutinib.
- FIG. 51 shows tumor weights at day 7 after inoculation with UPN-1 cells and treatment with CDK4/6 inhibitor, BTK inhibitor ibrutinib or a combination of CDK4/6 inhibitor with ibrutinib.
- FIG. 52 shows MCL infiltration properties quantified by qPCR-mediated relative determination of human Alu sequences detected in the spleen of representative CAM-MCL chicken embryos (JEKO-1) after treatment with Compound (1), BTK inhibitor ibrutinib, or combination of Compound (1) with ibrutinib.
- FIG. 53 shows MCL infiltration properties quantified by qPCR-mediated relative determination of human Alu sequences detected in the spleen of representative CAM-MCL chicken embryos (UPN-1) after treatment with Compound (1), BTK inhibitor ibrutinib, or combination of Compound (1) with ibrutinib.
- FIG. 54A shows MCL infiltration properties quantified by qPCR-mediated relative determination of human Alu sequences detected in the spleen of representative CAM-MCL chicken embryos (UPN-1 IbruR) after treatment with Compound (1), BTK inhibitor ibrutinib, or combination of Compound (1) with ibrutinib.
- FIG. 54B shows MCL infiltration properties quantified by qPCR-mediated relative determination of human Alu sequences detected in the spleen of representative CAM-MCL chicken embryos (UPN-1 IbruR) after treatment with Compound (1), BTK inhibitor ibrutinib, or combination of Compound (1) with ibrutinib.
- FIG. 55 shows MCL infiltration properties quantified by qPCR-mediated relative determination of human Alu sequences detected in bone marrow (BM) of representative CAM-MCL chicken embryos (JEKO-1) after treatment with Compound (1), BTK inhibitor ibrutinib, or combination of Compound (1) with ibrutinib.
- FIG. 56 shows MCL infiltration properties quantified by qPCR-mediated relative determination of human Alu sequences detected in bone marrow (BM) of representative CAM-MCL chicken embryos (UPN-1) after treatment with Compound (1), BTK inhibitor ibrutinib, or combination of Compound (1) with ibrutinib.
- FIG. 57 shows MCL infiltration properties quantified by qPCR-mediated relative determination of human Alu sequences detected in bone marrow (BM) of representative CAM-MCL chicken embryos (UPN-1 IbruR) after treatment with Compound (1), BTK inhibitor ibrutinib, or combination of Compound (1) with ibrutinib.
- compositions and methods for treating mantle cell lymphoma by administering to a subject in need thereof a pharmaceutical composition, the pharmaceutical composition comprising in a unit dosage form a therapeutically-effective amount of a compound described herein (e.g., Compound 1 or compound 1 or compound (1) or Compound (1)) or a pharmaceutically-acceptable salt thereof.
- a compound described herein e.g., Compound 1 or compound 1 or compound (1) or Compound (1)
- Compound l is 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8- dihydropyrido[2,3-d]pyrimidine-6-carbonitrile.
- Compound 1 is present in a salt form, e.g., 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7- oxo-7, 8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate salt (Compound 1 salt).
- the methods further comprise administering a second pharmaceutical composition comprising, in a unit dosage form, a therapeutically-effective amount of a second compound, for example an Bruton’s tyrosine kinase (BTK) inhibiting drug.
- the BTK inhibitor can be selected from but are not limited to Ibrutinib, Acalabrutinib, Zanubrutinib
- a compound disclosed herein can be of the formula: wherein:
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen;
- R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen;
- a compound disclosed herein can be of the formula: wherein:
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen;
- R 3 is C 2 -Ce alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen;
- a compound disclosed herein can be a pharmaceutically-acceptable salt of the formula: wherein:
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen;
- R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen;
- a compound disclosed herein can be a lactate salt of the formula: wherein:
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen;
- R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen;
- R 1 is cycloalkyl. In some embodiments, R 1 is C 2 -Cs cycloalkyl. In some embodiments, R 1 is an unsubstituted cyclopentyl. In some embodiments, R 1 is an unsubstituted cyclopentyl. In some embodiments, R 2 is CN. In some embodiments, R 3 is hydrogen.
- R 4 is -NR 5 R 6 .
- one of R 5 and R 6 is hydrogen.
- one of R 5 and R 6 is phenyl.
- one of R 5 and R 6 is phenyl substituted with heterocyclyl.
- one of R 5 and R 6 is phenyl substituted with heterocyclyl, wherein the heterocyclyl contains at least one ring nitrogen atom.
- one of R 5 and R 6 is phenyl substituted with C 2 -Cs heterocyclyl.
- one of R 5 and R 6 is phenyl substituted with Ce heterocyclyl.
- one of R 5 and R 6 is phenyl substituted with piperazinyl, wherein the piperazinyl is unsubstituted or substituted. In some embodiments, one of R 5 and R 6 is phenyl substituted with piperazinyl, wherein the piperazinyl is substituted with an alkyl. In some embodiments, one of R 5 and R 6 is phenyl substituted with 4-methyl piperazinyl. [0086] In some embodiments, R 4 is wherein:
- R 7 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , - SR 5 , or -NR 5 R 6 , each of which is unsubstituted or substituted, or hydrogen;
- R 8 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , - SR 5 , or -NR 5 R 6 , each of which is unsubstituted or substituted, or hydrogen; and R 9 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , - SR 5 , or -NR 5 R 6 , each of which is unsubstituted or substituted, or hydrogen.
- R 7 is hydrogen.
- R 8 is hydrogen.
- R 9 unsubstituted or substituted heterocyclyl. In some embodiments, R 9 is unsubstituted or substituted piperazinyl. In some embodiments, R 9 is piperazinyl substituted with alkyl. In some embodiments, R 9 is 4-methyl piperazinyl.
- the compound is a compound of formula (II)
- the compound is a compound of formula (III)
- Y is O, S, or NR 11 ; each R 10 is independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, -OR 5 , -SR 5 , or -NR 5 R 6 , each of which is unsubstituted or substituted;
- R 11 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, or heteroaryl, each of which is independently substituted or unsubstituted, or hydrogen or halogen; and n is 0, 1, 2, 3, 4, 5, 6, 7, or 8.
- R 1 is cycloalkyl. In some embodiments, R 1 is Cs-Cs cycloalkyl. In some embodiments, R 1 is an unsubstituted cyclopentyl. In some embodiments, R 1 is an unsubstituted cyclopentyl.
- Y is NR 11 .
- R 11 is alkyl.
- R 11 is methyl.
- n is 0.
- Y is NR 11 .
- R 11 is alkyl.
- R 11 is methyl.
- n is 0.
- the compound is of the formula:
- the compound is in the form of a salt formed by combining a compound with lactic acid.
- a compound disclosed herein is 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile monolactate.
- Several moieties described herein can be substituted or unsubstituted.
- optional substituents include hydroxyl groups, sulfhydryl groups, halogens, amino groups, nitro groups, nitroso groups, cyano groups, azido groups, sulfoxide groups, sulfone groups, sulfonamide groups, carboxyl groups, carboxaldehyde groups, imine groups, alkyl groups, halo-alkyl groups, alkenyl groups, halo-alkenyl groups, alkynyl groups, halo- alkynyl groups, alkoxy groups, aryl groups, aryloxy groups, aralkyl groups, arylalkoxy groups, heterocyclyl groups, acyl groups, acyloxy groups, carbamate groups, amide groups, ureido groups, epoxy groups, and ester groups.
- Non-limiting examples of alkyl groups include straight, branched, and cyclic alkyl groups.
- An alkyl group can be, for example, a Ci, C2, C3, C4, C5, Ce, C7, Cs, C9, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C 24 , C 25 , C 26 , C27, C 28 , C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, or C50 group that is substituted or unsubstituted.
- Non-limiting examples of straight alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl.
- Branched alkyl groups include any straight alkyl group substituted with any number of alkyl groups.
- Non-limiting examples of branched alkyl groups include isopropyl, isobutyl, sec-butyl, and t-butyl.
- Non-limiting examples of substituted alkyl groups includes hydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl, 1 -chloroethyl, 2 -hydroxy ethyl, 1,2- difluoroethyl, and 3-carboxypropyl.
- Non-limiting examples of cyclic alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptlyl, and cyclooctyl groups. Cyclic alkyl groups also include fused-, bridged-, and spiro-bicycles and higher fused-, bridged-, and spiro-systems. A cyclic alkyl group can be substituted with any number of straight, branched, or cyclic alkyl groups.
- Non-limiting examples of cyclic alkyl groups include cyclopropyl, 2-methyl- cycloprop-l-yl, cycloprop-2-en-l-yl, cyclobutyl, 2,3-dihydroxycyclobut-l-yl, cyclobut-2-en- 1-yl, cyclopentyl, cyclopent-2-en-l-yl, cyclopenta-2,4-dien-l-yl, cyclohexyl, cyclohex-2-en- 1-yl, cycloheptyl, cyclooctanyl, 2,5-dimethylcyclopent-l-yl, 3,5-dichlorocyclohex-l-yl, 4- hydroxycyclohex-l-yl, 3,3,5-trimethylcyclohex-l-yl, octahydropentalenyl, octahydro- 1/7- indenyl, 3a,4,5,6,7,7a-
- Non-limiting examples of alkenyl and alkenylene groups include straight, branched, and cyclic alkenyl groups.
- the olefin or olefins of an alkenyl group can be, for example, E, Z, cis, trans, terminal, or exo-methylene.
- An alkenyl or alkenylene group can be, for example, a C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , Cio, Cu, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, c 25 , C26, C27, C 28 , C29, C30, C31, C32, C33, C34, c 35 , C36, C37, C 38 , C39, C40, C41, C42, C43, C44, C45, C46, C47, c 48 , C49, or C50 group that is substituted or unsubstituted.
- Non-limiting examples of alkenyl and alkenylene groups include ethenyl, prop-l-en-l-yl, isopropenyl, but- l-en-4-yl; 2-chloroethenyl, 4-hydroxybuten-l-yl, 7-hydroxy-7-methyloct-4-en-2-yl, and 7- hy droxy-7 -methyloct-3 , 5 -dien-2-yl .
- Non-limiting examples of alkynyl or alkynylene groups include straight, branched, and cyclic alkynyl groups.
- the triple bond of an alkylnyl or alkynylene group can be internal or terminal.
- An alkylnyl or alkynylene group can be, for example, a C 2 , C3, C 4 , C5, Ce, C 7 , C 8 , C 9 , Cio, Cu, C12, C13, C14, C15, C16, C17, Cl 8 , C19, C 2 0, C 2 1, C 2 2, C 2 3, C 2 4, C 25 , C 2 6, C 2 7, C 28 , C29, C 30 , C31, C 32 , C 33 , C 34 , C 35 , C 36 , C 37 , C 38 , C 39 , C40, C41, c 42 , C 43 , C44, c 45 , C 46 , C47, C 48 , C49, or C50 group that
- Non-limiting examples of alkynyl or alkynylene groups include ethynyl, prop-2-yn-l-yl, prop-l-yn-l-yl, and 2-methyl-hex-4-yn-l- yl; 5-hydroxy-5-methylhex-3-yn-l-yl, 6-hydroxy-6-methylhept-3-yn-2-yl, and 5-hydroxy-5- ethylhept-3 -yn- 1 -yl .
- a halo-alkyl group can be any alkyl group substituted with any number of halogen atoms, for example, fluorine, chlorine, bromine, and iodine atoms.
- a halo-alkenyl group can be any alkenyl group substituted with any number of halogen atoms.
- a halo-alkynyl group can be any alkynyl group substituted with any number of halogen atoms.
- An alkoxy group can be, for example, an oxygen atom substituted with any alkyl, alkenyl, or alkynyl group.
- An ether or an ether group comprises an alkoxy group.
- alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, and isobutoxy.
- An aryl group can be heterocyclic or non-heterocyclic.
- An aryl group can be monocyclic or polycyclic.
- An aryl group can be substituted with any number of substituents described herein, for example, hydrocarbyl groups, alkyl groups, alkoxy groups, and halogen atoms.
- Non-limiting examples of aryl groups include phenyl, toluyl, naphthyl, pyrrolyl, pyridyl, imidazolyl, thiophenyl, and furyl.
- Non-limiting examples of substituted aryl groups include 3,4-dimethylphenyl, 4-/c/7-butyl phenyl, 4-cyclopropylphenyl, 4-diethylaminophenyl, 4-(trifluoromethyl)phenyl, 4-(difluoromethoxy)-phenyl, 4-(trifluoromethoxy)phenyl, 3- chlorophenyl, 4-chlorophenyl, 3, 4-di chlorophenyl, 2-fluorophenyl, 2-chlorophenyl, 2- iodophenyl, 3 -iodophenyl, 4-iodophenyl, 2-m ethylphenyl, 3 -fluorophenyl, 3 -methylphenyl, 3 -methoxy phenyl, 4-fluorophenyl, 4-methylphenyl, 4-m ethoxyphenyl, 2,3 -difluorophenyl, 3,4-difluoropheny
- Non-limiting examples of substituted aryl groups include 2-aminophenyl, 2-(N- methylamino)phenyl, 2-(7V,7V-dimethylamino)phenyl, 2-(7V-ethylamino)phenyl, 2-(N,N- diethylamino)phenyl, 3 -aminophenyl, 3-(7V-methylamino)phenyl, 3-(N,N- dimethylamino)phenyl, 3-(7V-ethylamino)phenyl, 3-(A,A-diethylamino)phenyl, 4- aminophenyl, 4-(A-methylamino)phenyl, 4-(A,A-dimethylamino)phenyl, 4-(N- ethylamino)phenyl, and 4-(7V,7V-diethylamino)phenyl.
- a heterocycle can be any ring containing a ring atom that is not carbon, for example, N, O, S, P, Si, B, or any other heteroatom.
- a heterocycle can be substituted with any number of substituents, for example, alkyl groups and halogen atoms.
- a heterocycle can be aromatic (heteroaryl) or non-aromatic.
- Non-limiting examples of heterocycles include pyrrole, pyrrolidine, pyridine, piperidine, succinamide, maleimide, morpholine, imidazole, thiophene, furan, tetrahydrofuran, pyran, and tetrahydropyran.
- heterocycles include: heterocyclic units having a single ring containing one or more heteroatoms, non-limiting examples of which include, diazirinyl, aziridinyl, azetidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolinyl, oxathiazolidinonyl, oxazolidinonyl, hydantoinyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, piperidin-2-onyl, 2,3,4,5-tetrahydro-17/-azepinyl, 2,3 -dihydro- 177-indole, and 1,2,3,
- heteroaryl include: i) heteroaryl rings containing a single ring, non-limiting examples of which include, 1,2,3,4-tetrazolyl, [l,2,3]triazolyl, [l,2,4]triazolyl, triazinyl, thiazolyl, 1/7-imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, thiophenyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4- dimethylaminopyridinyl; and ii) heteroaryl rings containing 2 or more fused rings one of which is a heteroaryl ring, non-limiting examples of which include: 7/7-purinyl, 9/7-purinyl, 6-amino-9Z7-purinyl, 5Z7-pyrrolo[3,2- ]pyrimidinyl, 7Z
- a compound herein can be least 1% pure, at least 2% pure, at least 3% pure, at least 4% pure, at least 5% pure, at least 6% pure, at least 7% pure, at least 8% pure, at least 9% pure, at least 10% pure, at least 11% pure, at least 12% pure, at least 13% pure, at least 14% pure, at least 15% pure, at least 16% pure, at least 17% pure, at least 18% pure, at least 19% pure, at least 20% pure, at least 21% pure, at least 22% pure, at least 23% pure, at least 24% pure, at least 25% pure, at least 26% pure, at least 27% pure, at least 28% pure, at least 29% pure, at least 30% pure, at least 31% pure, at least 32% pure, at least 33% pure, at least 34% pure, at least 35% pure, at least 36% pure, at least 37% pure, at least 38% pure, at least 39% pure, at least 40% pure, at least 4
- compositions include, for example, acid-addition salts and base-addition salts.
- the acid that is added to the compound to form an acid-addition salt can be an organic acid or an inorganic acid.
- a base that is added to the compound to form a base-addition salt can be an organic base or an inorganic base.
- Acid addition salts can arise from the addition of an acid to a compound disclosed herein.
- the acid is organic.
- the acid is inorganic.
- the acid is lactic acid, salicylic acid, tartaric acid, ascorbic acid, gentisinic acid, gluconic acid, glucaronic acid, saccaric acid, formic acid, benzoic acid, glutamic acid, pantothenic acid, acetic acid, propionic acid, butyric acid, fumaric acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p- toluenesulfonic acid, citric acid, oxalic acid, maleic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, nitrous acid, sulfuric acid, sulfurous acid, a phosphoric acid, or isonicotinic acid.
- the salt is an acid addition salt with lactic acid. In some embodiments, the salt is an acid addition salt of 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile with lactic acid.
- the salt is a lactate salt, a salicylate salt, a tartrate salt, an ascorbate salt, a gentisinate salt, a gluconate salt, a glucaronate salt, a saccarate salt, a formate salt, a benzoate salt, a glutamate salt, a pantothenate salt, an acetate salt, a propionate salt, a butyrate salt, a fumarate salt, a succinate salt, a methanesulfonate salt, an ethanesulfonate salt, a benzenesulfonate salt, a p-toluenesulfonate salt, a citrate salt, an oxalate salt, a maleate salt, hydrochloride salt, a hydrobromide salt, a hydroiodide salt, a nitrate salt, a nitrite salt, a sulfate salt,
- the salt is a lactate salt. In some embodiments, the salt is a monolactate salt. In some embodiments, the compound is 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8- dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.
- Metal salts can arise from the addition of an inorganic base to a compound disclosed herein.
- the inorganic base consists of a metal cation paired with a basic counterion, such as, for example, hydroxide, carbonate, bicarbonate, or phosphate.
- the metal can be an alkali metal, alkaline earth metal, transition metal, or main group metal.
- the metal is lithium, sodium, potassium, cesium, cerium, magnesium, manganese, iron, calcium, strontium, cobalt, titanium, aluminum, copper, cadmium, or zinc.
- a metal salt is a lithium salt, a sodium salt, a potassium salt, a cesium salt, a cerium salt, a magnesium salt, a manganese salt, an iron salt, a calcium salt, a strontium salt, a cobalt salt, a titanium salt, an aluminum salt, a copper salt, a cadmium salt, or a zinc salt.
- a compound described herein can down-modulate these kinase pathways, or a portion thereof, for example, cyclin-dependent kinases (CDK), e.g., a CDK inhibitor.
- CDK cyclin-dependent kinases
- a CDK inhibitor is a compound disclosed herein.
- Non-limiting examples of CDK inhibitors are listed in Table 1.
- overexpression of CDK e.g., CDK 4/6 causes cell-cycle deregulation in cancers.
- modulation of kinase pathways can result in the obstruction of proliferation signal receipt in cells, thus arresting tumor growth.
- CDK4/6 inhibition can arrest the cell cycle (e.g., through repression of positive regulators of the G2/M cell cycle phase, or increase in G1 cell cycle fraction and G1 blockade).
- the CDK inhibitor is a compound disclosed herein. In some embodiments, the CDK inhibitor is a CDK4/6 inhibitor. In some embodiments, the CDK4/6 inhibitor is a compound of formula (I), or a pharmaceutically-acceptable salt thereof. In some embodiments, a compound disclosed herein comprises a compound of formula (I), or a pharmaceutically-acceptable salt thereof. In some embodiments, a compound of formula (I) comprises 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8- dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof.
- 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo- 7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof is compound (1).
- a method disclosed herein comprises administering to the subject a therapeutically-effective amount of a compound disclosed herein or a pharmaceutically-acceptable salt thereof. In some embodiments, a method disclosed herein comprises administering to the subject a therapeutically-effective amount of a compound (1) or a pharmaceutically-acceptable salt thereof.
- a compound disclosed herein has an enhanced antitumor activity compared to other CDK inhibitors. In some embodiments, a compound disclosed herein has an enhanced antitumor activity compared to palbociclib. In some embodiments, a compound disclosed herein has an enhanced antitumor activity compared to ribociclib. In some embodiments, a compound disclosed herein has an enhanced antitumor activity compared to abemaciclib. In some embodiments, a compound disclosed herein has a greater antitumor activity compared to trilaciclib. In some embodiments, enhanced antitumor activity comprises enhanced tumor growth inhibition. In some embodiments, enhanced antitumor activity comprises increased apoptosis. In some embodiments, enhanced antitumor activity comprises enhanced cell proliferation inhibition.
- a compound disclosed herein has superior activity compared to other CDK inhibitors. In some embodiments, a compound disclosed herein has superior activity compared to palbociclib. In some embodiments, a compound disclosed herein has superior activity compared to ribociclib. In some embodiments, a compound disclosed herein has superior activity compared to abemaciclib. In some embodiments, a compound disclosed herein has superior activity compared to trilaciclib.
- a compound disclosed herein represses one or more positive regulators of the G2/M cell cycle phase. In some embodiments, a compound disclosed herein increases loss of phospho-Histone H3. In some embodiments, a compound disclosed herein downregulates phospho-Histone H3/CDK2. In some embodiments, a compound disclosed herein triggers accumulation of CDK inhibitors p21, pl 6, and/or phospho-p27. In some embodiments, a compound disclosed herein upregulates p21, pl 6, and/or phospho-p27. In some embodiments, a compound disclosed herein triggers CDK2 dephosphorylation. In some embodiments, a compound disclosed herein increases a G1 cell cycle blockade. In some embodiments, a compound disclosed herein increases mitochondrial apoptosis.
- the B cell receptor signaling pathway is essential for B cell development and antibody production and is often affected in hemopoietic cancers, including mantle cell lymphoma.
- a compound described herein can down-modulate the B cell receptor signaling pathway, or a portion thereof, for example, Bruton tyrosine kinase (BTK).
- BTK Bruton tyrosine kinase
- overexpression of BTK causes cell-cycle deregulation in cancers.
- modulation of kinase pathways can result in the obstruction of proliferation signal receipt in cells, thus arresting tumor growth.
- a compound described herein can be an inhibitor of tyrosine kinases.
- a compound described herein can be an inhibitor of Bruton’s tyrosine kinase (BTK).
- BTK Bruton’s tyrosine kinase
- the dual inhibitory effect of a compound described herein provides a therapeutic strategy to improve efficacy of BTK inhibition and reduce emergence of resistance.
- the present disclosure provides a method for the use of a compound disclosed herein, for example, for treating cancer.
- Cancer is a collection of related diseases characterized by uncontrolled proliferation of cells with the potential to metastasize throughout the body. Cancer can be classified into five broad categories including, for example: carcinomas, which can arise from cells that cover internal and external parts of the body such as the lung, breast, and colon; sarcomas, which can arise from cells that are located in bone, cartilage, fat, connective tissue, muscle, and other supportive tissues; lymphomas, which can arise in the lymph nodes and immune system tissues; leukemia, which can arise in the bone marrow and accumulate in the bloodstream; and adenomas, which can arise in the thyroid, the pituitary gland, the adrenal gland, and other glandular tissues.
- carcinomas which can arise from cells that cover internal and external parts of the body such as the lung, breast, and colon
- sarcomas which can arise from cells that are located in bone, cartilage, fat, connective tissue, muscle, and other supportive tissues
- lymphomas which can arise in the lymph nodes and immune system tissues
- leukemia which can
- the cancer is a solid tumor cancer.
- the cancer is carcinoma.
- carcinoma include: adenocarcinoma, basal cell carcinoma, squamous cell carcinoma, and transitional cell carcinoma.
- the cancer is sarcoma.
- sarcomas include: bone sarcomas and soft tissue sarcomas.
- the sarcoma is a soft tissue sarcoma.
- soft-tissue sarcomas include: chondrosarcoma, rhabdomysarcoma, and leiomyosarcoma.
- the cancer is lymphoma.
- lymphoma include: subsets of lymphoma, Hodgkin lymphoma, Non-Hodgkin lymphoma, B cell lymphoma, Diffuse large B-cell lymphoma (DLBCL), Mantle cell lymphoma (MCL), Lymphoblastic lymphoma, Burkitt lymphoma (BL), Primary mediastinal (thymic) large B- cell lymphoma (PMBCL), Transformed follicular and transformed mucosa-associated lymphoid tissue (MALT) lymphomas, High-grade B-cell lymphoma with double or triple hits (HBL), Primary cutaneous DLBCL, leg type, Primary DLBCL of the central nervous system, Primary central nervous system (CNS) lymphoma, Acquired immunodeficiency syndrome (AIDS)-associated lymphoma, Follicular lymphoma (FL), Marginal zone lymphoma (MZL),
- DLBCL Diffuse large B
- the cancer is breast cancer.
- the cancer is hormone receptor-positive (HR+), HER2-negative metastatic breast cancer.
- the cancer is triple negative breast cancer (TNBC).
- the cancer is lung cancer.
- the cancer is colon cancer.
- the cancer is Mantle cell lymphoma (MCL).
- the cancer is BTKi-resistant MCL.
- the cancer is B-cell non-Hodgkin lymphoma (B-NHL).
- the cancer is a carcinoma of the bladder, breast, colon (e.g., colorectal carcinomas such as colon adenocarcinoma and colon adenoma), kidney, epidermis, liver, lung, for example adenocarcinoma, small cell lung cancer and non-small cell lung carcinomas, esophagus, gall bladder, ovary, pancreas e.g., exocrine pancreatic carcinoma, stomach, cervix, thyroid, nose, head and neck, prostate, or skin, for example squamous cell carcinoma; a hematopoietic tumor of lymphoid lineage, for example leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, B-cell lymphoma (such as diffuse large B cell lymphoma), T-cell lymphoma, multiple myeloma, mantle cell lymphoma, Hodgkin’s lymphoma, non-Hodg
- the cancer is a cancer sensitive to inhibition of one or more cyclin dependent kinases, e.g., CDK4 sensitive cancer, CDK6 sensitive cancer, CDK4/6 sensitive cancer.
- cyclin dependent kinases e.g., CDK4 sensitive cancer, CDK6 sensitive cancer, CDK4/6 sensitive cancer.
- the cancer is associated with dysregulation of a gene, e.g., overexpression or underexpression of a gene, e.g., BUB1, BRCA.
- the cancer is associated with dysregulation of a transcription factor, e.g., overexpression or underexpression of a transcription factor, e.g., MYC, E2F.
- the cancer is a cancer comprising cancer stem cells (CSCs), e.g., breast cancer.
- CSCs cancer stem cells
- the cancer is a refractory cancer.
- the cancer is a relapsed cancer.
- the cancer is resistant and/or non-responsive to a first line of therapy.
- the cancer is associated with poor prognosis and/or low survival probability.
- the cancer is a cancer of a reproductive organ.
- the reproductive organ cancer is a breast cancer, ovarian cancer, e.g., serous ovarian cancer, e.g., low grade serous ovarian cancer, endometrial cancer.
- the breast cancer is a primary breast cancer.
- the breast cancer is a secondary breast cancer.
- the breast cancer is a metastatic breast cancer.
- the breast cancer is hormone receptor positive.
- the breast cancer is estrogen receptor positive.
- the breast cancer is estrogen receptor negative.
- the breast cancer is progesterone receptor positive.
- the breast cancer is progesterone receptor negative.
- the breast cancer is HER2 receptor negative. In some embodiments, the breast cancer is estrogen receptor positive and progesterone receptor positive. In some embodiments, the breast cancer is estrogen receptor positive and progesterone receptor negative. In some embodiments, the breast cancer is estrogen receptor negative and progesterone receptor positive. In some embodiments, the breast cancer is estrogen receptor negative and progesterone receptor negative. In some embodiments, the breast cancer is estrogen receptor positive, progesterone receptor positive, and HER2 receptor negative. In some embodiments, the breast cancer is estrogen receptor positive, progesterone receptor negative, and HER2 receptor negative. In some embodiments, the breast cancer is estrogen receptor negative, progesterone receptor positive, and HER2 receptor negative. In some embodiments, the breast cancer is estrogen receptor negative, progesterone receptor positive, and HER2 receptor negative. In some embodiments, the breast cancer is estrogen receptor negative, progesterone receptor positive, and HER2 receptor negative.
- the breast cancer is estrogen receptor negative, progesterone receptor negative, and HER2 receptor negative. In some embodiments, the breast cancer is TNBC. In some embodiments, the breast cancer is a BRCA positive. In some embodiments, the breast cancer shows BUB1 expression, e.g., very high, high, low, or very low expressions of BUB1. In some embodiments, the breast cancer does not show BUB1 expression, e.g., detectable BUB 1 expression. In some embodiments, the breast cancer showing high expression of BUB1 is associated with low survival probability. In some embodiments, the breast cancer is a refractory and/or relapsed breast cancer.
- Non-limiting examples of tumors that are treatable by a combination of a compound described herein can include solid tumors, solid tumors that are refractory to prior treatment with conventional chemotherapy, and solid tumors that respond to initial chemotherapy but subsequently relapsed.
- the tumor is a breast cancer tumor.
- the tumor is a metastatic breast cancer tumor.
- the breast cancer tumor is hormone receptor positive.
- the breast cancer tumor is estrogen receptor positive.
- the breast cancer tumor is estrogen receptor negative.
- the breast cancer tumor is progesterone receptor positive.
- the breast cancer tumor is progesterone receptor negative.
- the breast cancer tumor is HER2 receptor negative.
- the breast cancer tumor is estrogen receptor positive and progesterone receptor positive. In some embodiments, the breast cancer tumor is estrogen receptor positive and progesterone receptor negative. In some embodiments, the breast cancer tumor is estrogen receptor negative and progesterone receptor positive. In some embodiments, the breast cancer tumor is estrogen receptor negative and progesterone receptor negative. In some embodiments, the breast cancer tumor is estrogen receptor positive, progesterone receptor positive, and HER2 receptor negative. In some embodiments, the breast cancer tumor is estrogen receptor positive, progesterone receptor negative, and HER2 receptor negative. In some embodiments, the breast cancer tumor is estrogen receptor negative, progesterone receptor positive, and HER2 receptor negative. In some embodiments, the breast cancer tumor is estrogen receptor negative, progesterone receptor positive, and HER2 receptor negative. In some embodiments, the breast cancer tumor is estrogen receptor negative, progesterone receptor positive, and HER2 receptor negative.
- the breast cancer tumor is estrogen receptor negative, progesterone receptor negative, and HER2 receptor negative. In some embodiments, the breast cancer tumor is TNBC. In some embodiments, the breast cancer tumor is a BRCA positive. In some embodiments, the breast cancer tumor shows BUB1 expression, e.g., very high, high, low, or very low expressions of BUB1. In some embodiments, the breast cancer tumor does not show BUB1 expression, e.g., detectable BUB 1 expression. In some embodiments, the breast cancer tumor showing high expression of BUB1 is associated with low survival probability. In some embodiments, the breast cancer tumor is a refractory and/or relapsed.
- a method disclosed herein can be used to treat, for example, an infectious disease, a proliferative disease, a cancer, a solid tumor, or a liquid tumor.
- tumors that are treatable by a combination of a compound described herein can include solid tumors, solid tumors that are refractory to prior treatment with conventional chemotherapy, and solid tumors that respond to initial chemotherapy but subsequently relapsed.
- the tumor is a solid tumor.
- solid tumors include: carcinomas, sarcomas, and lymphomas.
- the solid tumor is a carcinoma.
- the solid tumor is a sarcoma.
- the solid tumor is a lymphona.
- the tumor is a mantle cell lymphoma tumor.
- a tumor response due to a method herein can be measured based on the Response Evaluation Criteria in Solid Tumors (RECIST) classification of responses.
- RECIST Response Evaluation Criteria in Solid Tumors
- To use RECIST requires at least one tumor that can be measured on x-rays, CT scans, or MRI scans.
- RECIST assigns four categories of response: complete response (CR), a partial response (PR), progressive disease (PD), and stable disease (SD).
- Key features of the RECIST include definitions of minimum size of measurable lesions, instructions on how many lesions to follow, and the use of uni dimensional, rather than bidimensional, measures for overall evaluation of tumor burden.
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a compound of formula (I), or a pharmaceutically-acceptable salt thereof.
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of 8-cyclopentyl- 2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof.
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of 8- cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile monolactate.
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a compound of formula (I), or a pharmaceutically-acceptable salt thereof.
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of 8-cyclopentyl- 2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof.
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of 8- cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile monolactate.
- the present disclosure provides a method of treating Bruton tyrosine kinase inhibitor-resistant mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a compound of formula (I), or a pharmaceutically-acceptable salt thereof.
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically- effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8- dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof.
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.
- the present disclosure provides a method of treating Bruton tyrosine kinase inhibitor-resistant mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a compound of formula (I), or a pharmaceutically-acceptable salt thereof.
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically- effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8- dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof.
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.
- the subject is further treated with a BTK inhibitor, e.g., acalabrutinib.
- the 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo- 7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate and the BTK inhibitor, e.g., acalabrutinib are administered concurrently.
- the subject is further treated with a BTK inhibitor, e.g., acalabrutinib.
- the 8-cyclopentyl-2- ((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile monolactate is administered before administering the BTK inhibitor, e.g., acalabrutinib.
- the 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate is administered after administering the BTK inhibitor, e.g., acalabrutinib.
- the administering comprises a second line of therapy.
- the subject received a therapy other than the compound for the mantle cell lymphoma (e.g., BTK inhibitor such as ibrutinib or acalabrutinib) prior to the administering.
- the therapy e.g., BTK inhibitor such as ibrutinib
- the subject did not respond to the therapy (e.g., BTK inhibitor such as ibrutinib or acalabrutinib).
- the subject experienced a relapse of the mantle cell lymphoma after the therapy (e.g., BTK inhibitor such as ibrutinib acalabrutinib).
- BTK inhibitor such as ibrutinib acalabrutinib
- the subject has primary resistance to one or more BTK inhibitors, e.g., acalabrutinib.
- the subject has acquired resistance to one or more BTK inhibitors e.g., acalabrutinib.
- a method disclosed herein comprises administering to the subject a therapeutically-effective amount of a compound of formula (I), or a pharmaceutically-acceptable salt thereof.
- a compound disclosed herein comprises a compound of formula (I), or a pharmaceutically-acceptable salt thereof.
- a compound of formula (I) comprises 8-cyclopentyl-2-((4-(4- methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof.
- 8- cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof is compound (1).
- Cancer development is a multistep process where genetic changes are accumulated, thus progressively transforming cells into a cancerous phenotype.
- one or more genes associated with cellular proliferation is upregulated in a cell of a subject having a cancer disclosed herein.
- one or more genes associated with a protein exposed on or secreted from the cell surface is downregulated in a cell of a subject having a cancer disclosed herein.
- administering a compound disclosed herein alters expression of one or more genes in a cell of a subject having a cancer disclosed herein.
- a compound disclosed herein downregulates expression of one or more differentially expressed genes in a cell of a subject having a cancer disclosed herein. In some embodiments, a compound disclosed herein downregulates a gene associated with DNA repair. In some embodiments, a compound disclosed herein downregulates a gene associated with G2/M checkpoints. In some embodiments, a compound disclosed herein downregulates a gene associated with E2F targets. In some embodiments, a compound disclosed herein downregulates a gene associated with MYC targets. In some embodiments, a compound disclosed herein downregulates a gene associated with TNFa signaling. In some embodiments, a compound disclosed herein downregulates a gene associated with inflammatory response.
- a compound disclosed herein upregulates expression of one or more differentially expressed genes in a cell of a subject having a cancer disclosed herein. In some embodiments, a compound disclosed herein upregulates a gene associated with DNA repair. In some embodiments, a compound disclosed herein upregulates a gene associated with G2/M checkpoints. In some embodiments, a compound disclosed herein upregulates a gene associated with E2F targets. In some embodiments, a compound disclosed herein upregulates a gene associated with MYC targets. In some embodiments, a compound disclosed herein upregulates a gene associated with TNFa signaling. In some embodiments, a compound disclosed herein upregulates a gene associated with inflammatory response.
- the present disclosure also provides method for using such a compound disclosed herein, for example, 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8- dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof with one or more additional therapeutic agents.
- Methods disclosed herein further include administering one or more additional agents to treat a disease or disorder in a combination therapy.
- a combination therapy comprises administering a compound disclosed herein, for example, 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, with (concurrently, simultaneously, or sequentially) a second agent.
- a compound disclosed herein for example, 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof.
- the compounds described herein for example, 8-cyclopentyl-2-((4-(4- methylpiperazin-1 yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof, can be used in combination with agents disclosed herein or other suitable agents, depending on the condition being treated.
- the one or more compounds disclosed herein are co-administered with a second agent.
- the compounds described herein are administered with the second agent simultaneously or separately. This administration in combination can include simultaneous administration of the two agents in the same dosage form, simultaneous administration in separate dosage forms, and separate administration.
- a compound described herein and a second agent can be formulated together in the same dosage form and administered simultaneously.
- a compound disclosed herein and a second agent can be simultaneously administered, wherein both the agents are present in separate formulations.
- a compound disclosed herein can be administered just followed by a second agent, or vice versa.
- a compound disclosed herein and a second agent are administered a one or more minutes apart, one or more hours apart, or one or more days apart.
- the second agent is a biological, pharmaceutical, or chemical compound.
- a second agent include a simple or complex organic or inorganic molecule, a peptide, a protein, an oligonucleotide, an epigenetic modulator, hormones (steroidal or peptide), fusion molecules, an antibody, an antibody derivative, antibody fragment, a vitamin derivative, a carbohydrate, a toxin, a vaccine, e.g., cancer vaccine, a chemotherapeutic compound, radiotherapies (y-rays, X-rays, and/or the directed delivery of radioisotopes, microwaves, and UV radiation), gene therapies (e.g., antisense, retroviral therapy) and other immunotherapies.
- a second agent examples include small molecule inhibitors, monoclonal antibodies (mAbs), sdAbs, chimeric antigen receptors (CARs), CAR T-cell therapy, and antibody-drug conjugates (ADCs), and bispecific antibodies.
- a second agent is a biologic.
- Biologicales include vaccines, blood, and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins.
- the method includes administering a procedure.
- procedures include surgery, radiation treatments (i.e., beam radiation), chemotherapy, immunotherapy, and ablation.
- a combination therapy includes the combination of one or more compounds of the disclosure with a second agent to provide a synergistic or additive therapeutic effect.
- the second therapeutic agent is an autophagy initiating inhibitor, e.g., a small molecule kinase inhibitor, e.g., ULK1/2 inhibitor, e.g., SBI-0206965 (SB I).
- the second therapeutic agent is anAOK5 inhibitor.
- the second therapeutic agent is an autophagy inhibitor, e.g., chloroquine, hydroxychloroquine.
- the second therapeutic agent is an aromatase inhibitor.
- the aromatase inhibitor is letrozole or a pharmaceutically- acceptable salt thereof.
- the second therapeutic agent is a selective estrogen receptor degrader.
- the second therapeutic agent is a selective estrogen receptor blocker.
- the selective estrogen receptor degrader is fulvestrant.
- the second therapeutic agent is an autophagy agent, e.g., hydroxychloroquine, chloroquine.
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8- dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with a second therapeutic agent.
- a compound of formula (I) such as 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8- dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with a second therapeutic agent.
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with an estrogen receptor modulator.
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with an estrogen receptor modulator.
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with an estrogen receptor blocker, e.g., an aromatase inhibitor such as letrozole or a pharmaceutically- acceptable salt thereof.
- an estrogen receptor blocker e.g., an aromatase inhibitor such as letrozole or a pharmaceutically- acceptable salt thereof.
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with a progestin such as megestrol or esters thereof (e.g., megestrol acetate).
- a progestin such as megestrol or esters thereof (e.g., megestrol acetate).
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with an estrogen receptor degrader such as fulvestrant.
- an estrogen receptor degrader such as fulvestrant.
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with an angiogenesis inhibitor.
- a compound of formula (I) such as 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with an angiogenesis inhibitor.
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with a vascular endothelial growth factor (VEGF) inhibitor.
- VEGF vascular endothelial growth factor
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4-methylpiperazin- l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with a phosphoinositide 3 -kinase (PI3K) inhibitor.
- a combination therapy includes administration of two, three, four, or five additional agents in combination with a compound disclosed herein.
- the third therapeutic agent can be a therapeutic agent disclosed herein.
- the fourth therapeutic agent can be a therapeutic agent disclosed herein.
- the fifth therapeutic agent can be a therapeutic agent disclosed herein.
- the present disclosure provides a combination and method for using such of a compound disclosed herein, for example, 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, with a BTK inhibitor, for example ibrutinib or a pharmaceutically-acceptable salt thereof, or acalabrutinib or a pharmaceutically-acceptable salt thereof.
- a BTK inhibitor for example ibrutinib or a pharmaceutically-acceptable salt thereof, or acalabrutinib or a pharmaceutically-acceptable salt thereof.
- the present disclosure provides a combination and method for using a compound disclosed herein, for example, 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7- oxo-7, 8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof.
- a compound disclosed herein comprises 8-cyclopentyl-2-((4- (4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof, administered in combination with a BTK inhibitor.
- a compound disclosed herein, for example Compound 1 is administered in combination with a BTK inhibitor.
- a BTK inhibitor comprises ibrutinib or a pharmaceutically- acceptable salt thereof. In some embodiments, a BTK inhibitor comprises acalabrutinib or a pharmaceutically-acceptable salt thereof. In some embodiments, a BTK inhibitor comprises pirtobrutinib (Loxo-305) or a pharmaceutically acceptable salt thereof.
- a compound disclosed herein for example 8-cyclopentyl-2- ((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with ibrutinib or a pharmaceutically-acceptable salt thereof.
- a compound disclosed herein for example 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with acalabrutinib or a pharmaceutically-acceptable salt thereof.
- a compound disclosed herein for example 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8- dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with pirtobrutinib (Loxo-305) or a pharmaceutically acceptable salt thereof.
- a compound of formula (I), such as 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with a second compound, e.g., a drug.
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with a BTK inhibitor.
- a compound of formula (I) such as 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with a BTK inhibitor.
- the BTK inhibitor is ibrutinib or a pharmaceutically-acceptable salt thereof.
- the BTK inhibitor is acalabrutinib or a pharmaceutically- acceptable salt thereof.
- the BTK inhibitor is pirtobrutinib (Loxo-305) or a pharmaceutically-acceptable salt thereof.
- the BTK inhibitor is zanubrutinib or a pharmaceutically-acceptable salt thereof.
- the BTK inhibitor is tirabrutinib or a pharmaceutically-acceptable salt thereof.
- the BTK inhibitor is tolebrutinib or a pharmaceutically-acceptable salt thereof.
- the BTK inhibitor is evobrutinib or a pharmaceutically-acceptable salt thereof. In some embodiments, the BTK inhibitor is fenebrutinib or a pharmaceutically-acceptable salt thereof. In some embodiments, the BTK inhibitor is spebrutinib or a pharmaceutically- acceptable salt thereof.
- a compound of the disclosure for example, a compound of formula (I) or a pharmaceutically-acceptable salt thereof, is administered in combination with a second compound.
- a compound of the disclosure for example 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is administered in combination with a second compound
- a second compound is a drug.
- a second compound is a BTK inhibitor.
- the present disclosure provides a pharmaceutical combination comprising a compound of the disclosure, e.g., a compound of formula (I), such as 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, and a second compound, e.g., a drug.
- a compound of the disclosure e.g., a compound of formula (I), such as 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, and a second compound, e.g., a drug.
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is in combination with a BTK inhibitor.
- the BTK inhibitor can be ibrutinib or a pharmaceutically-acceptable salt thereof.
- the BTK inhibitor can be acalabrutinib or a pharmaceutically- acceptable salt thereof.
- the compound of formula (I) and the second compound can be in a one pharmaceutical composition. In some embodiments, the compound of formula (I) and the second compound can be in separate pharmaceutical compositions.
- the present disclosure provides a pharmaceutical combination comprising a compound of the disclosure, e.g., a compound of formula (I), such as 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, and a second compound, e.g., a drug.
- a compound of formula (I) such as 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile or
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is in combination with ibrutinib or a pharmaceutically acceptable salt thereof.
- a compound of formula (I) such as 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is in combination with ibrutinib or a pharmaceutically acceptable salt thereof.
- 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile or a pharmaceutically-acceptable salt thereof is compound (1).
- the combination of compound (1) and ibrutinib a pharmaceutically-acceptable salt thereof achieves synergistic antitumor activity.
- the synergistic antitumor activity is shown against a BTK inhibitor-resistant MCL.
- the present disclosure provides a pharmaceutical combination comprising a compound of the disclosure, e.g., a compound of formula (I), such as 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, and a second compound, e.g., a drug.
- a compound of the disclosure e.g., a compound of formula (I), such as 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, and a second compound, e.g., a drug.
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is in combination with acalabrutinib or a pharmaceutically acceptable salt thereof.
- the combination of compound (1) and acalabrutinib or a pharmaceutically acceptable salt thereof achieves synergistic antitumor activity.
- the synergistic antitumor activity is shown against a BTK inhibitor-resistant MCL.
- the present disclosure provides a pharmaceutical combination comprising a compound of the disclosure, e.g., a compound of formula (I), such as 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, and a second compound, e.g., a drug.
- a compound of the disclosure e.g., a compound of formula (I), such as 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, and a second compound, e.g., a drug.
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is in combination with pirtobrutinib (Loxo-305) or a pharmaceutically acceptable salt thereof.
- the combination of compound (1) and pirtobrutinib (Loxo-305) or a pharmaceutically acceptable salt thereof achieves synergistic antitumor activity.
- the synergistic antitumor activity is shown against a BTK inhibitor-resistant MCL.
- the synergistic antitumor activity is cytotoxic synergy. In some embodiments, the synergy comprises increased antitumor activity compared to monotherapy. In some embodiments, the synergy comprises increased antitumor activity compared to monotherapy comprising a compound disclosed herein. In some embodiments, the synergy comprises increased antitumor activity compared to monotherapy comprising a compound disclosed herein. In some embodiments, the synergy comprises increased antitumor activity compared to monotherapy comprising the second compound. In some embodiments the synergy comprises increased cytotoxic activity compared to monotherapy. In some embodiments the synergy comprises increased cytotoxic activity compared to monotherapy comprising a compound disclosed herein. In some embodiments the synergy comprises increased cytotoxic activity compared to monotherapy comprising the second compound.
- the second compound exhibits an additive therapeutic effect to the compound of formula (I). In some embodiments, the compound of formula (I), exhibits an additive therapeutic effect to the second compound. In some embodiments, the second compound exhibits an additive therapeutic effect to the compound of formula (I). In some embodiments, the compound of formula (I), exhibits an additive therapeutic effect to the second compound.
- the compound of formula (I) evokes G1 cell cycle blockade.
- a second compound administered in combination with the compound of formula (I) increases G1 cell cycle blockade compared to monotherapy comprising compound of formula (I).
- a compound disclosed herein e.g., the compound of formula (I) is administered in combination with a second CDK 4/6 inhibitor.
- the present disclosure provides a pharmaceutical combination comprising a compound of the disclosure, e.g., a compound of formula (I), such as 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, and a second compound, e.g., a drug.
- a compound of the disclosure e.g., a compound of formula (I), such as 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, and a second compound, e.g., a drug.
- a compound of the disclosure e.g., a compound of formula (I), such as 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, is in combination with acalabrutinib.
- the combination of compound (1) and acalabrutinib achieves significant synergistic antitumor activity.
- the synergistic antitumor activity is shown against a BTK inhibitor-resistant MCL.
- Bruton’s tyrosine kinase is a kinase which plays a key role in B cell development.
- BTK contains five protein interaction domains and functions to transmit signals from the pre-B cell receptor during B cell development. Activation of BTKs encourages B- cell proliferation. The suppression of BTK in mantle cell lymphoma can be achieved by inhibiting BTK.
- Non-limiting examples of BTK inhibitors include: ibrutinib, acalabrutinib, zanubrutinib, tirabrutinib, tolebrutinib, evobrutinib, fenebrutinib, spebrutinib, and pirtobrutinib (Loxo-305).
- Ibrutinib is a small molecule drug that irreversibly binds to the BTK protein. Blocking BTK inhibits the B cell receptor pathway, which is often aberrantly active in B cell cancers. Treatment of B cell cancers with ibrutinib significantly lowers B cell proliferation.
- the BTK inhibitor is ibrutinib or a pharmaceutically-acceptable salt thereof.
- the structure of ibrutinib is depicted below.
- the BTK inhibitor is acalabrutinib or a pharmaceutically- acceptable salt thereof.
- the structure of acalabrutinib is depicted below. 4- ⁇ 8-amino-3 - [(2 S)- 1 -(but-2-ynoyl)pyrrolidin-2-yl]imidazo[ 1 ,5-a]pyrazin- 1 -yl ⁇ -N-(pyridin- 2-yl)benzamide.
- a pharmaceutically-acceptable salt of 4- ⁇ 8-amino-3-[(2S)-l-(but-2- ynoyl)pyrrolidin-2-yl]imidazo[l,5-a]pyrazin-l-yl ⁇ -N-(pyridin-2-yl)benzamide can also be used.
- Unc-51-like kinase 1/2 (ULK 1/2) inhibitors inhibit the phosphorylation of ULK1 or ULK2, which regulates autophagy and lysosomal fusion, thereby blocking autophagy flux.
- ULK plays critical role during initial stages of autophagy which is a vital response to nutrient starvation.
- ULK1/2 is an essential and early autophagy regulator that are frequently activated in many cancers, e.g., KRAS mutant cancers.
- Non-limiting examples of ULK 1/ 2 include SBI-0206965 (SBI), MRT68921, DCC-3116, MRT67307, or pharmaceutical salts thereof.
- Phosphoinositide 3-kinase (PI3K) inhibitors inhibit one or more of the phosphoinositide 3-kinase enzymes. These enzymes form part of the PI3K/AKT/mT0R pathway, which is a pathway involved in cell growth and survival, and other processes that are frequently activated in many cancers. By inhibiting these enzymes, PI3K inhibitors cause cell death, inhibit the proliferation of malignant cells, and interfere with several signaling pathways. PI3K inhibitors are usually given to treat certain cancers that have relapsed or are unresponsive to other cancer treatments. Non-limiting examples of PI3K inhibitors include alpelisib, copanlisib, duvelisib, and idelalisib.
- Small molecule inhibitors of autophagy can suppress tumor growth both in vitro and in vivo. Inhibition of autophagy sensitizes cancer cells to therapy, enhancing the cytotoxic effects induced by chemotherapeutic agents.
- Autophagy is a key pathway in the development of endocrine resistance in breast cancer. In some embodiments, targeting autophagy can reverse antiestrogen resistance.
- Autophagy inhibitors can be weak bases. Non-limiting examples of autophagy inhibitors include hydroxychloroquine (HCQ), chloroquine (CQ).
- HCQ hydroxychloroquine
- CQ chloroquine
- the unprotonated form of CQ/HCQ can diffuse through cell membranes and enter into organelles such as lysosomes, where the high concentration of H+ induces their protonation and consequently increases lysosomal pH.
- AMPK-related protein kinase 5 regulates Atk-dependent cell survival and migration (e.g., formation of metastases) through inhibition of cellular metabolism.
- ARK5 overexpression is found in multiple tumors and is associated with poor prognosis in metastatic breast cancer, multiple myeloma, and hepatocellular carcinoma.
- inhibition of ARK5 induces cell death through PI3K/AKT/mT0R pathway.
- a compound disclosed herein for example, 8-cyclopentyl-2-((4-(4-methylpiperazin- l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile (formula 1) or a pharmaceutically-acceptable salt thereof, can be formulated as a capsule.
- a capsule can be a hard capsule.
- a capsule can be a soft capsule.
- a capsule can be a soft gelatin capsule.
- a compound disclosed herein can be formulated as a hard capsule, the hard capsule comprising an amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate equivalent to 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8- dihydropyrido[2,3-d]pyrimidine-6-carbonitrile.
- a compound described herein can be formulated as a tablet.
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising, in a unit dosage form, an amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, equivalent to 40 mg of a compound described herein.
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising, in a unit dosage form, an amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate, equivalent to 40 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8- dihydropyrido[2,3-d]pyrimidine-6-carbonitrile.
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising, in a unit dosage form, 48.4 mg of 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile monolactate.
- 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7- oxo-7, 8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt is administered in oral capsules, swallowed with water in the morning in a fasted state, at least 1 hour before ingesting food. In some embodiments, a morning dose is taken after an overnight fast an hour before ingesting food. In some embodiments, a compound described herein is administered every day. In some embodiments, a compound described herein is administered every day for 4 weeks.
- a compound described herein is administered on a 4-week cycle of: (i) a continuous, three-week period of once-daily administration; and (ii) immediately following the three-week period, one week of no administration. In some embodiments, a compound described herein is administered every 2 days.
- a compound disclosed herein for example, ibrutinib or a pharmaceutically - acceptable salt thereof, can be formulated as capsule or a tablet.
- ibrutinib or a pharmaceutically-acceptable salt thereof can be formulated as a capsule, the capsule comprising, in a unit dosage form, a therapeutically-effective amount of ibrutinib or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable excipient.
- ibrutinib or a pharmaceutically-acceptable salt thereof can be formulated as a tablet, the tablet comprising, in a unit dosage form, a therapeutically-effective amount of ibrutinib, and a pharmaceutically-acceptable excipient.
- ibrutinib or a pharmaceutically-acceptable salt thereof is provided as an about 70 mg or about 140 mg capsule for oral administration.
- the capsule can be colored (e.g., yellow) or not colored (e.g., white).
- the capsule shell can contain gelatin, titanium dioxide, yellow iron oxide and/or black ink.
- Inactive ingredients can include croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and/or sodium lauryl sulfate.
- ibrutinib or a pharmaceutically-acceptable salt thereof is provided as an about 140 mg, about 280 mg, about 420 mg, or about 560 mg tablet for oral administration.
- the tablets can be colored (e.g., yellow, purple, green, or orange), and can be uncoated or film-coated.
- a film coating can contain ferrosoferric oxide, polyvinyl alcohol, polyethylene glycol, red iron oxide, talc, titanium dioxide, and/or yellow iron oxide.
- Inactive ingredients can include colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and/or sodium lauryl sulfate.
- ibrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of one about 560 mg tablet administered once a day with water. In some embodiments, ibrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of two about 280 mg tablets, which can be taken in one dose or in two doses daily (e.g., once per day or twice per day). In some embodiments, ibrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of four about 140 mg tablets, which can be taken in one dose or multiple doses (e.g., two, three or four doses per day).
- ibrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of an about 420 mg tablet administered once a day with water. In some embodiments, ibrutinib or a pharmaceutically- acceptable salt thereof is given at a dose of an about 280 mg tablet administered once a day with water. In some embodiments, ibrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of an about 140 mg tablet administered once a day with water. In some embodiments, ibrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of an about 70 mg tablet administered once a day with water.
- ibrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of one about 560 mg capsule administered once a day with water. In some embodiments, ibrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of two about 280 mg capsules, which can be taken in one dose or in two doses daily (e.g., once per day or twice per day). In some embodiments, ibrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of four about 140 mg capsules, which can be taken in one dose or multiple doses (e.g., two, three or four doses per day).
- ibrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of an about 420 mg capsule administered once a day with water. In some embodiments, ibrutinib or a pharmaceutically- acceptable salt thereof is given at a dose of an about 280 mg capsule administered once a day with water. In some embodiments, ibrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of an about 140 mg capsule administered once a day with water. In some embodiments, ibrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of an about 70 mg capsule administered once a day with water.
- a daily dose of ibrutinib or a pharmaceutically-acceptable salt thereof can be taken in a single tablet. In some embodiments, a daily dose of ibrutinib or a pharmaceutically-acceptable salt thereof can be taken in a single capsule. In some embodiments, a daily dose of ibrutinib or a pharmaceutically-acceptable salt thereof can be taken in multiple tablets. In some embodiments, a daily dose of ibrutinib or a pharmaceutically-acceptable salt thereof can be taken in multiple capsules.
- a daily dose is about 560 mg
- the daily dose can be administered in an about 560 mg tablet taken once a day, two about 280 mg tablets taken together in one dose, two about 280 mg tablets taken apart (e.g., twice daily), four about 140 mg tablets taken together in one dose, or four about 140 mg tablets taken apart (e.g., twice, thrice, or four times daily).
- Acalabrutinib is administered in an about 560 mg tablet taken once a day, two about 280 mg tablets taken together in one dose, two about 280 mg tablets taken apart (e.g., twice daily), four about 140 mg tablets taken together in one dose, or four about 140 mg tablets taken apart (e.g., twice, thrice, or four times daily).
- a compound disclosed herein for example, acalabrutinib or a pharmaceutically- acceptable salt thereof, can be formulated as capsule or a tablet.
- acalabrutinib or a pharmaceutically-acceptable salt thereof can be formulated as a capsule, the capsule comprising, in a unit dosage form, a therapeutically-effective amount of acalabrutinib or a pharmaceutically-acceptable salt thereof, and a pharmaceutically- acceptable excipient.
- acalabrutinib or a pharmaceutically-acceptable salt thereof can be formulated as a tablet, the tablet comprising, in a unit dosage form, a therapeutically-effective amount of acalabrutinib, and a pharmaceutically-acceptable excipient.
- acalabrutinib or a pharmaceutically-acceptable salt thereof is provided as an about 70 mg or about 140 mg capsule for oral administration.
- the capsule can be colored (e.g., yellow) or not colored (e.g., white).
- the capsule shell can contain gelatin, titanium dioxide, yellow iron oxide and/or black ink.
- Inactive ingredients can include croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and/or sodium lauryl sulfate.
- acalabrutinib or a pharmaceutically-acceptable salt thereof is provided as an about 140 mg, about 280 mg, about 420 mg, or about 560 mg tablet for oral administration.
- the tablets can be colored (e.g., yellow, purple, green, or orange), and can be uncoated or film-coated.
- a film coating can contain ferrosoferric oxide, polyvinyl alcohol, polyethylene glycol, red iron oxide, talc, titanium dioxide, and/or yellow iron oxide.
- Inactive ingredients can include colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and/or sodium lauryl sulfate.
- acalabrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of one about 560 mg tablet administered once a day with water. In some embodiments, acalabrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of two about 280 mg tablets, which can be taken in one dose or in two doses daily (e.g., once per day or twice per day). In some embodiments, acalabrutinib or a pharmaceutically- acceptable salt thereof is given at a dose of four about 140 mg tablets, which can be taken in one dose or multiple doses (e.g., two, three or four doses per day).
- acalabrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of an about 420 mg tablet administered once a day with water. In some embodiments, acalabrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of an about 280 mg tablet administered once a day with water. In some embodiments, acalabrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of an about 140 mg tablet administered once a day with water. In some embodiments, acalabrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of an about 70 mg tablet administered once a day with water.
- acalabrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of one about 560 mg capsule administered once a day with water. In some embodiments, acalabrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of two about 280 mg capsules, which can be taken in one dose or in two doses daily (e.g., once per day or twice per day). In some embodiments, acalabrutinib or a pharmaceutically- acceptable salt thereof is given at a dose of four about 140 mg capsules, which can be taken in one dose or multiple doses (e.g., two, three or four doses per day).
- acalabrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of an about 420 mg capsule administered once a day with water. In some embodiments, acalabrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of an about 280 mg capsule administered once a day with water. In some embodiments, acalabrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of an about 140 mg capsule administered once a day with water. In some embodiments, acalabrutinib or a pharmaceutically-acceptable salt thereof is given at a dose of a 70 mg capsule administered once a day with water.
- a daily dose of acalabrutinib or a pharmaceutically-acceptable salt thereof can be taken in a single tablet. In some embodiments, a daily dose of acalabrutinib or a pharmaceutically-acceptable salt thereof can be taken in a single capsule. In some embodiments, a daily dose of acalabrutinib or a pharmaceutically-acceptable salt thereof can be taken in multiple tablets. In some embodiments, a daily dose of acalabrutinib or a pharmaceutically-acceptable salt thereof can be taken in multiple capsules.
- a daily dose is about 560 mg
- the daily dose can be administered in an about 560 mg tablet taken once a day, two about 280 mg tablets taken together in one dose, two about 280 mg tablets taken apart (e.g., twice daily), four about 140 mg tablets taken together in one dose, or four about 140 mg tablets taken apart (e.g., twice, thrice, or four times daily).
- a pharmaceutical composition of the disclosure can be a combination of any pharmaceutical compounds described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients.
- a pharmaceutical composition of the disclosure can comprise Compound 1 or Compound 1 salt and a pharmaceutically acceptable excipient. The pharmaceutical composition facilitates administration of the compound to an organism.
- compositions can be administered in therapeutically-effective amounts as pharmaceutical compositions by various forms and routes including, for example, intravenous, subcutaneous, intramuscular, inhalation, oral, parenteral, ophthalmic, otic, subcutaneous, transdermal, nasal, intravitreal, intratracheal, intrapulmonary, transmucosal, vaginal, and topical administration.
- routes including, for example, intravenous, subcutaneous, intramuscular, inhalation, oral, parenteral, ophthalmic, otic, subcutaneous, transdermal, nasal, intravitreal, intratracheal, intrapulmonary, transmucosal, vaginal, and topical administration.
- Formulations can be modified depending upon the route of administration chosen.
- Pharmaceutical compositions comprising a compound described herein can be manufactured, for example, by mixing, dissolving, emulsifying, encapsulating, entrapping, or compression processes.
- Non-limiting examples of dosage forms suitable for use in a method disclosed herein include feed, food, pellet, lozenge, liquid, elixir, aerosol, inhalant, spray, powder, tablet, pill, capsule, gel, geltab, nanosuspension, nanoparticle, microgel, suppository troches, aqueous or oily suspensions, ointment, patch, lotion, dentifrice, emulsion, creams, drops, dispersible powders or granules, emulsion in hard or soft gel capsules, syrups, phytoceuticals, nutraceuticals, and any combination thereof.
- compositions can be formulated by combining the active compounds with pharmaceutically-acceptable carriers or excipients.
- pharmaceutically-acceptable excipients suitable for use in the method disclosed herein include granulating agents, binding agents, lubricating agents, disintegrating agents, sweetening agents, glidants, anti -adherents, anti-static agents, surfactants, anti-oxidants, gums, coating agents, coloring agents, flavoring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifying agents, anti-microbial agents, plant cellulosic material and spheronization agents, and any combination thereof.
- Non-limiting examples of pharmaceutically-acceptable carriers include saline solution, Ringer’s solution and dextrose solution. Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the compound disclosed herein, where the matrices are in the form of shaped articles, such as films, liposomes, microparticles, and microcapsules.
- compositions can be formulated by combining the active compounds with pharmaceutically-acceptable carriers or excipients into a unit dosage form which can be solid or liquid.
- oral solid forms include tablets, powders, pills, dragees, capsules, liquids, gels, syrups, elixirs, slurries, or suspensions for oral ingestion by a subject.
- Pharmaceutical preparations for oral use can be obtained by mixing one or more solid excipients with one or more compounds described herein, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Cores can be provided with suitable coatings.
- concentrated sugar solutions can be used.
- the solutions can contain an excipient such as gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments can be added to the tablets or dragee coatings, for example, for identification or to characterize different combinations of active compound doses.
- compositions that can be used orally include push-fit capsules made of gelatin and soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- Pharmaceutical preparations that can be used orally include coated and uncoated tablets.
- the capsule comprises a hard gelatin capsule, the capsule comprising one or more of pharmaceutical, bovine, and plant gelatins.
- a gelatin can be alkaline-processed.
- the capsule or tablet can contain the active ingredients in admixture with filler such as lactose, binders such as starches, or lubricants such as talc or magnesium stearate, and stabilizers.
- the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. Stabilizers can be added. All formulations for oral administration are provided in dosages suitable for such administration.
- compositions can be formulated by combining the active compounds with pharmaceutically-acceptable carriers or excipients.
- Such carriers can be used to formulate liquids, gels, syrups, elixirs, slurries, or suspensions, for oral ingestion by a subject.
- Non-limiting examples of solvents used in an oral dissolvable formulation can include water, ethanol, isopropanol, saline, physiological saline, DMSO, dimethylformamide, potassium phosphate buffer, phosphate buffer saline (PBS), sodium phosphate buffer, 4-2-hy droxy ethyl- 1 -piperazineethanesulfonic acid buffer (HEPES), 3-(N-morpholino)propanesulfonic acid buffer (MOPS), piperazine-N,N'-bis(2- ethanesulfonic acid) buffer (PIPES), and saline sodium citrate buffer (SSC).
- Non-limiting examples of co-solvents used in an oral dissolvable formulation can include sucrose, urea, cremaphor, DMSO, and potassium phosphate buffer.
- Parenteral injections can be formulated for bolus injection or continuous infusion.
- the pharmaceutical compositions can be in a form suitable for parenteral injection as a sterile suspension, solution, or emulsion in oily or aqueous vehicles such as saline or water for injection, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Suspensions of the active compounds can be prepared as oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
- the suspension can also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- the active compounds can be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams, and ointments.
- Such pharmaceutical compositions can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
- the compounds of the disclosure can be applied topically to the skin, or a body cavity, for example, oral, vaginal, bladder, cranial, spinal, thoracic, or pelvic cavity of a subject.
- the compounds of the disclosure can be applied to an accessible body cavity.
- the compounds can also be formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, and synthetic polymers such as polyvinylpyrrolidone and PEG.
- rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas
- conventional suppository bases such as cocoa butter or other glycerides
- synthetic polymers such as polyvinylpyrrolidone and PEG.
- a low-melting wax such as a mixture of fatty acid glycerides, optionally in combination with cocoa butter, can be used.
- compositions can be tablets, lozenges, or gels.
- Formulations suitable for transdermal administration of the active compounds can employ transdermal delivery devices and transdermal delivery patches, and can be lipophilic emulsions or buffered aqueous solutions, dissolved, or dispersed in a polymer or an adhesive. Such patches can be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical compounds. Transdermal delivery can be accomplished by iontophoretic patches. Transdermal patches can provide controlled delivery. The rate of absorption can be slowed by using rate-controlling membranes or by trapping the compound within a polymer matrix or gel.
- Absorption enhancers can be used to increase absorption.
- An absorption enhancer or carrier can include absorbable pharmaceutically-acceptable solvents to assist passage through the skin.
- transdermal devices can be in the form of a bandage comprising a backing member, a reservoir containing compounds and carriers, a rate controlling barrier to deliver the compounds to the skin of the subject at a controlled and predetermined rate over a prolonged period of time, and adhesives to secure the device to the skin or the eye.
- the active compounds can be in a form as an aerosol, a vapor, a mist, or a powder. Inhalation can occur through by nasal delivery, oral delivery, or both.
- Nasal or intranasal administration involves insufflation of compounds through the nose, for example, nasal drops and nasal sprays. This route of administration can result in local and/or systemic effects.
- Inhaler or insufflator devices can be used for nose-to-lung delivery of compounds described herein.
- a pharmaceutical composition can be administered in a local or systemic manner, for example, via injection of the compound directly into an organ, optionally in a depot or sustained release formulation or implant.
- Pharmaceutical compositions can be provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation.
- a rapid release form can provide an immediate release.
- An extended release formulation can provide a controlled release or a sustained delayed release.
- therapeutically- effective amounts of the compounds described herein are administered in pharmaceutical compositions to a subject having a disease or condition to be treated.
- the subject is a mammal such as a human.
- a therapeutically-effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compounds used, and other factors.
- the compounds can be used singly or in combination with one or more therapeutic agents as components of mixtures.
- compositions comprising the compounds described herein include formulating the compounds with one or more inert, pharmaceutically- acceptable excipients or carriers to form a solid, semi-solid, or liquid composition.
- Solid compositions include, for example, powders, tablets, dispersible granules, capsules, and cachets.
- Liquid compositions include, for example, solutions in which a compound is dissolved, emulsions comprising a compound, or a solution containing liposomes, micelles, or nanoparticles comprising a compound as disclosed herein.
- Semi-solid compositions include, for example, gels, suspensions, and creams.
- compositions can be in liquid solutions or suspensions, solid forms suitable for solution or suspension in a liquid prior to use, or as emulsions. These compositions can also contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and other pharmaceutically-acceptable additives.
- Non-limiting examples of dosage forms suitable for use in the disclosure include liquid, powder, gel, nanosuspension, nanoparticle, microgel, aqueous or oily suspensions, emulsion, and any combination thereof.
- Non-limiting examples of pharmaceutically-acceptable excipients suitable for use in the disclosure include binding agents, disintegrating agents, anti-adherents, anti-static agents, surfactants, anti-oxidants, coating agents, coloring agents, plasticizers, preservatives, suspending agents, emulsifying agents, anti-microbial agents, spheronization agents, solubilizers, stabilizers, tonicity enhancing agents, buffers and any combination thereof.
- a composition of the disclosure can be, for example, an immediate release form or a controlled release formulation.
- An immediate release formulation can be formulated to allow the compounds to act rapidly.
- Non-limiting examples of immediate release formulations include readily dissolvable formulations.
- a controlled release formulation can be a pharmaceutical formulation that has been adapted such that release rates and release profiles of the active agent can be matched to physiological and chronotherapeutic requirements or, alternatively, has been formulated to effect release of an active agent at a programmed rate.
- controlled release formulations include granules, delayed release granules, hydrogels (e.g., of synthetic or natural origin), other gelling agents (e.g., gelforming dietary fibers), matrix-based formulations (e.g., formulations comprising a polymeric material having at least one active ingredient dispersed through), granules within a matrix, polymeric mixtures, and granular masses.
- a controlled release formulation is a delayed release form.
- a delayed release form can be formulated to delay a compound’s action for an extended period of time.
- a delayed release form can be formulated to delay the release of an effective dose of one or more compounds, for example, for about 4, about 8, about 12, about 16, or about 24 h.
- a controlled release formulation can be a sustained release form.
- a sustained release form can be formulated to sustain, for example, the compound’s action over an extended period of time.
- a sustained release form can be formulated to provide an effective dose of any compound described herein (e.g., provide a physiologically-effective blood profile) over about 4, about 8, about 12, about 16, or about 24 h.
- Non-limiting examples of pharmaceutically-acceptable excipients can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington’s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), each of which is incorporated by reference in its entirety.
- Subjects can be, for example, elderly adults, adults, adolescents, pre-adolescents, children, toddlers, infants, neonates, and non-human animals.
- a subject is a patient.
- compositions of a compound disclosed herein can comprise a liquid comprising an active agent in solution, in suspension, or both.
- Liquid compositions can include gels.
- the liquid composition is aqueous.
- the composition can be an ointment.
- the composition is an in situ gellable aqueous composition.
- the composition is an in situ gellable aqueous solution.
- a pharmaceutically-acceptable excipient can be present in a pharmaceutical composition at a mass of between about 0.1% and about 99% by mass of the composition.
- a pharmaceutically-acceptable excipient can be present in a pharmaceutical composition at a mass of between about 0.1% and about 95%, between about 0.1% and about 90%, between about 0.1% and about 85%, between about 0.1% and about 80%, between about 0.1% and about 75%, between about 0.1% and about 70%, between about 0.1% and about 65%, between about 0.1% and about 60%, between about 0.1% and about 55%, between about 0.1% and about 50%, between about 0.1% and about 45%, between about 0.1% and about 40%, between about 0.1% and about 35%, between about 0.1% and about 30%, between about 0.1% and about 25%, between about 0.1% and about 20%, between about 0.1% and about 15%, between about 0.1% and about 10%, between about 0.1% and about 5%, or between about 0.1% and about 1%, by mass of the formulation.
- a pharmaceutically-acceptable excipient can be present at about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 26%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, about 50%, about 51%, about 52%, about
- Subjects can be, humans for example, elderly adults, adults, adolescents, preadolescents, children, toddlers, infants, neonates, and non-human animals, e.g., a mouse.
- a subject is a patient.
- a subject has experienced and/or exhibited at least one symptom of the disease or disorder to be treated and/or reduced in likelihood to occur.
- the subject has been identified or diagnosed as having a cancer described herein, e.g., breast cancer.
- the subject has a cancer and/or tumor that is positive for ibrutinib resistance.
- the subject is predisposed and/or at risk to having a cancer, e.g., breast cancer, based on presence of a mutation in a gene, e.g., BRCA1 mutation.
- the subject has received a first line of therapy.
- the subject is resistant and/or non-responsive to the first line of therapy.
- a method of treatment disclosed herein comprises, identification of a patient population based on one or more selection criteria, e.g., biomarkers, failure to respond to a primary therapy and administering a compound disclosed herein, e.g., Compound 1 to treat the patient.
- the patient population selection criteria can include but are not limited to, presence of a biomarker, e.g., marker associate with a particular disease, a marker associated with poor prognosis of a disease, failure to respond to an initial therapy, age, gender, health of the patient.
- the screening procedure may include but are not limited to blood and/or tissue sample analysis, genetic tests, genetic screening, biopsy, drug sensitivity/resistance test.
- compositions of a compound disclosed herein can comprise a liquid comprising an active agent in solution, in suspension, or both.
- Liquid compositions can include gels.
- the liquid composition is aqueous.
- the composition is an ointment.
- the composition is an in situ gellable aqueous composition.
- the composition is an in situ gellable aqueous solution.
- compositions described herein can be in unit dosage forms suitable for single administration of precise dosages.
- the formulation is divided into unit doses containing appropriate quantities of one or more compounds.
- the unit dosage can be in the form of a package containing discrete quantities of the formulation.
- Nonlimiting examples are packaged injectables, vials, or ampoules.
- Aqueous suspension compositions can be packaged in single-dose non-reclosable containers. Multiple-dose reclosable containers can be used, for example, in combination with or without a preservative.
- Formulations for parenteral injection can be presented in unit dosage form, for example, in ampoules, or in multi-dose containers with a preservative.
- a compound described herein can be present in a composition in a range of from about 1 mg to about 5 mg, from about 5 mg to about 10 mg, from about 10 mg to about 15 mg, from about 15 mg to about 20 mg, from about 20 mg to about 25 mg, from about 25 mg to about 30 mg, from about 30 mg to about 35 mg, from about 35 mg to about 40 mg, from about 40 mg to about 45 mg, from about 45 mg to about 50 mg, from about 50 mg to about 55 mg, from about 55 mg to about 60 mg, from about 60 mg to about 65 mg, from about 65 mg to about 70 mg, from about 70 mg to about 75 mg, from about 75 mg to about 80 mg, from about 80 mg to about 85 mg, from about 85 mg to about 90 mg, from about 90 mg to about 95 mg, from about 95 mg to about 100 mg, from about 100 mg to about 125 mg, from about 125 mg to about 150 mg, from about 150 mg to about 175 mg, from about 175 mg to about 200 mg, from about 200 mg to about 225 mg, from about 225
- a compound described herein can be present in a composition in an amount of about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 120 mg, about 140 mg, about 160 mg, about 180 mg, about 200 mg, about 220 mg, about 240 mg, about 260 mg, about 280 mg, about 300 mg, about 320 mg, about 340 mg, about 360 mg, about 380 mg, about 400 mg, about 420 mg, about 440 mg, about 460 mg, about 480 mg, about 500 mg, about 520 mg, about 540 mg, about 560 mg, about 580 mg, or about 600 mg.
- a compound described herein can be administered to a subject in an amount of about 0.1 mg/kg to about 500 mg/kg, about 1 mg/kg to about 500 mg/kg, about 0.1 mg/kg to about 300 mg/kg, about 1 mg/kg to about 300 mg/kg, or about 0.1 mg/kg to about 30 mg/kg.
- the compound disclosed herein is administered to a subject in an amount of about 1 mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about 6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10 mg/kg, about 11 mg/kg, about 12 mg/kg, about 13 mg/kg, about 14 mg/kg, about 15 mg/kg, about 16 mg/kg, about 17 mg/kg, about 18 mg/kg, about 19 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30 mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg, about 55 mg/kg, about 60 mg/kg, about 65 mg/kg, about 70 mg/kg, about 75 mg/kg, about 80 mg/kg, about 85 mg/kg, about 90 mg/kg, about 95 mg/kg, about 100 mg/kg, about 120 mg/kg, about 150 mg/kg, about 160 mg/kg, about
- a dosing regimen disclosed herein can be, for example, once a day, twice a day, thrice a day, once a week, twice a week, or thrice a week.
- a compound disclosed herein is administered once daily.
- a compound disclosed herein is administered once daily for 28 days (one cycle).
- a compound disclosed herein is administered once daily in one or more 28 day cycles.
- a compound disclosed herein is administered in a four-week cycle of consecutive once daily administration for three weeks, followed by one week with no administrations.
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a compound of formula (I) wherein:
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen;
- R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen;
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a compound of formula (I) wherein:
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen;
- R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen;
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of a compound of formula (I) wherein:
- R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl or heterocyclyl, each of which is unsubstituted or substituted, or hydrogen;
- R 3 is alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, each of which is unsubstituted or substituted, or hydrogen or halogen;
- a compound described herein can be administered before, during, or after the occurrence of a disease or condition, and the timing of administering the composition containing a compound can vary.
- a compound can be used as a prophylactic and can be administered continuously to subjects with a propensity to conditions or diseases to lessen or reduce a likelihood of the occurrence of the disease or condition.
- a compound and composition can be administered to a subject during or as soon as possible after the onset of the symptoms.
- the administration of a compound can be initiated within the first 48 hours of the onset of the symptoms, within the first 24 hours of the onset of the symptoms, within the first 6 hours of the onset of the symptoms, or within 3 hours of the onset of the symptoms.
- the initial administration can be via any route practical, such as by any route described herein using any formulation described herein.
- a compound can be administered as soon as is practical after the onset of a disease or condition is detected or suspected, and for a length of time necessary for the treatment of the disease, such as, for example, from about 1 month to about 3 months.
- the length of time a compound can be administered can be about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 2 months, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 3 months, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 4 months, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 5 months, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 13 months, about 14 months, about 15 months, about 20 weeks, about
- a dosing schedule for administration of a compound described herein can be consistent for the length of the dosing regimen.
- a compound can be administered daily.
- a dosing schedule for administration of a compound described herein can include portions of time where dosing is paused. For example, a compound can be administered every day for 3 weeks and then not be administered for one week.
- a dosing schedule for administration of a compound described herein can include once daily (QD), twice daily (BID), three times daily (TID), four times daily (QID), once weekly, twice weekly, three times weekly, once monthly, twice monthly, and once every other month.
- a daily dose can be given in a single dose or divided into multiple doses to be administered in intervals, e.g., twice daily or three times daily.
- a daily dose of 100 mg can be given, for example, once daily (100 mg), twice daily (50 mg per dose).
- a compound of the disclosure is administered in combination with, before, or after treatment with another therapeutic agent, e.g., a drug, such as an aromatase inhibitor.
- a compound of the disclosure is administered at regular intervals, such as, for example, once daily, twice daily, thrice daily, etc. and the second therapeutic agent is administered daily or intermittently or on an as-needed basis.
- the multiple therapeutic agents can be provided in a single, unified form, or in multiple forms, for example, as multiple separate unit dosage forms.
- the agents can be packed together or separately, in a single package or in a plurality of packages.
- One or all the therapeutic agents can be given in multiple doses. If not simultaneous, the timing between the multiple doses can vary to as much as about a month.
- a dosing regimen disclosed herein can be, for example, one dose of 40 mg, one dose of 80 mg, one dose of 120 mg, one dose of 160 mg, or one dose of 200 mg of oral 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt per day.
- the dosing regimen disclosed herein can be, for example, 40 mg twice daily, 60 mg twice daily, 80 mg twice daily, or 100 mg twice daily.
- the dosing is oral.
- 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7- oxo-7, 8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt is administered once daily.
- 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt is administered once daily for 28 days (one cycle).
- 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8- dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt is administered once daily in one or more 28 day cycles.
- 8-cyclopentyl- 2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile is administered in a four-week cycle of consecutive once daily administration for three weeks, followed by one week with no administrations.
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, wherein the administering is once daily for at least 4 weeks.
- the present disclosure provides a method of treating mantle cell lymphoma in a subject in need thereof, the method comprising administering to the subject a therapeutically-effective amount of 8-cyclopentyl-2-((4-(4-methylpiperazin-l yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile or a pharmaceutically-acceptable salt thereof, wherein the administering is a 4-week cycle of: (i) a continuous, three-week period of once-daily administration; and ii) immediately following the three-week period, one week of no administration.
- a dosing regimen disclosed herein can be, for example, once a day, twice a day, thrice a day, once a week, twice a week, or thrice a week.
- the dosing is oral.
- a BTK inhibitor disclosed herein is ibrutinib or a pharmaceutically-acceptable salt thereof or acalabrutinib or a pharmaceutically-acceptable salt thereof.
- a suitable amount ibrutinib or a pharmaceutically- acceptable salt thereof or acalabrutinib or a pharmaceutically-acceptable salt thereof can range from about 50 mg to about 600 mg per day, for example about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 120 mg, about 140 mg, about 160 mg, about 180 mg, about 200 mg, about 220 mg, about 240 mg, about 260 mg, about 280 mg, about 300 mg, about 320 mg, about 340 mg, about 360 mg, about 380 mg, about 400 mg, about 420 mg, about 440 mg, about 460 mg, about 480 mg, about 500 mg, about 520 mg, about 540 mg, about 560 mg, about 580 mg, or about 600 mg per day, based on the mass of ibrutinib or acalabrutinib.
- a composition of the disclosure binds to different cellular proteins than a comparator molecule. In some embodiments, a composition of the disclosure binds to different cellular proteins than palbociclib. In some embodiments, a composition of the disclosure binds to one or more of the following cellular proteins : CDC42BPB, CHEK1, DGCR6, MAP-KAPK5, TBK1, UVSSA, ZNF260, AAK1, ATAT1, AURKA, BMP2K, BUB1, CDK2, CDK5, CPQ, EPHA2, FKBP8, GSK3A, GSK3B, LIMK1, MAP11, PER3, SLK, STK17A, STK17B, TFEB, TGFBR2, USF2, ZCRB1, ACAA1, AIFM2, ANP32B, AP2A1, AP2M1, AP2S1, AVEN, BOD1L1, CDK12, CDK7, CDKN1A, CHEK1, COG8, DECR
- Non-limiting examples of a comparator include palbociclib, abemaciclib, and riboci clib.
- a composition of the disclosure deregulates cellular phosphopeptide levels. In some embodiments, a composition of the disclosure deregulates a unique cellular phosphopeptide profile compared to a comparator molecule. In some embodiments, a composition of the disclosure deregulates one or more peptides selected from the list consisting of: PRKD1, ULK1, RAFI, MAP2K2, CAMK2D, LYN, PRKD2, AKT2, TLK1, GTF2F1, STK3, CAMK1, LATS1, BRAF, NUAK1, HCK, BUB1, ARAF, MAP2K5, CDK16, and MAPK7.
- a composition disclosed herein modulate expression of one or more genes selected from one or more of RCAP3, CD86, SNX20, TAGAP, ZNF782, TAPRPL, ACOX1, NCOA1, FCRL1, NCF2, DALRD3, CLRA1, PFKFR2, MFSD3, NCKAPIL, C2orf81, PTTG1, FAM22C, HMGN2, CFNPF, PPL1RAP7, CDC20, CENPW, AUPKR, CCNR2, HMMP, DLGAP5, SPC25, PIF1, RPA3, PRC1, RIPC5, NDCRO, CDK1, HMGR2, ITGR1RP2, FLK1, KIFAR, TD3, TURAIR, CEP55, LIGI, PHF19, CFNPH, H2AZ2, NIF2, LTB, CCL22, MARCKSL1, EEF1A1, BLTP2, CUX1, CD83, and HNRNPA2B1.
- a composition disclosed herein overexpresses the expression of one or more genes selected from RCAP3, CD86, SNX20, TAGAP, ZNF782, TAPRPL, ACOX1, NCOA1, FCRL1, NCF2, DALRD3, CLRA1, PFKFR2, MFSD3, NCKAPIL, C2orf81, LTB, CCL22, MARCKSL1, EEF1A1, BLTP2, CUX1, and CD83.
- a composition disclosed herein suppresses the expression of one or more genes selected from PTTG1, FAM22C, HMGN2, CFNPF, PPL1RAP7, CDC20, CENPW, AUPKR, CCNR2, HMMP, DLGAP5, SPC25, PIF1, RPA3, PRC1, RIPC5, NDCRO, CDK1, HMGR2, ITGR1RP2, FLK1, KIFAR, TD3, TURAIR, CEP55, LIGI, PHF19, CFNPH, H2AZ2, NIF2, and HNRNPA2B1.
- EXAMPLE 1 Study to Evaluate an Oral Pharmaceutical Composition Disclosed Herein for Treating a Disease in a Subject.
- This study is a dose escalation study to investigate the safety, tolerability, and PK characteristics of 8-cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo- 7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile [compound (1)] in patients with advanced cancers who have received and failed at least one prior treatment.
- the primary objective of this study is to assess the safety and tolerability of repeated daily dosing of compound 1 in patients with relapsed and/or refractory advanced cancers.
- the secondary objective of this study is to establish a maximum tolerated dose (MTD) and a recommend phase 2 dose (RP2D) of orally administered compound (1).
- MTD maximum tolerated dose
- R2D recommend phase 2 dose
- the study explores efficacy of compound (1) in cancer patients.
- Study Design This study is a dose finding study using 3+3 design for dose escalation. Three to six patients are enrolled per dose cohort, followed by up to 12 additional patients at the RP2D. Approximately 36 patients with advanced cancers are enrolled in the study, based on 4 dose levels and an expansion cohort. If additional dose escalations are required to establish the MTD/RP2D, then 3-6 additional patients are added per dose level.
- Compound (1) is given in the form of a hard capsule comprising 48.4 mg 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile monolactate, equivalent to 40 mg of 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile.
- the initial dose is 40 mg (one capsule) taken once daily for 28 days (one cycle).
- Dose increments in the dose escalation 3+3 study are 40 mg of compound (1) per cycle. Dose levels are 40mg, 80mg, 120 mg, 160mg, etc., until a RP2D/MTD is reached.
- Each of the first three patients in the first and subsequent cohorts is assessed for dose limiting toxicities (DLT) during the first 28 days of treatment. If no patients experience a DLT, then enrollment to the next cohort begins at the next dose level. If one patient of the first three patients in a cohort experiences a DLT in the first 28 days, then an additional three patients are enrolled to that cohort for a total of six patients.
- DLT dose limiting toxicities
- the primary objective of this study is to assess the safety and tolerability of repeated daily dosing of compound (1) in patients with relapsed and/or refractory advanced cancers.
- the primary endpoints include (DLTs, adverse events (AEs), deaths and other serious AEs.
- the secondary objectives of this study are to establish a MTD of compound (1) and a RP2D of orally administered compound (1) and to characterize pharmacokinetics of compound (1) following oral administration in patients with relapsed and/or refractory advanced cancers. Secondary endpoints include maximum plasma concentration (Cmax), area under the plasma concentration time curve (AUC), and half-life (t 1/2).
- Exploratory objectives of this study are to assess the efficacy of compound (1), by objective responses per RECIST, wherever appropriate for applicable tumors.
- Assessment of non- Hodgkin's Lymphoma and CNS tumors is by imaging techniques (CT, PET, MRI).
- PK pharmacokinetic
- Compound (1) concentrations are determined in plasma samples by a validated liquid chromatographytandem mass spectrometry (LC-MS/MS) assay. Levels of compound (1) are determined at specified time points in the PK profile.
- LC-MS/MS liquid chromatographytandem mass spectrometry
- PK parameters are derived using model-independent analysis: time to reach Cmax (Tmax), Cmax, PA, AUCO-t, AUCO-a, CL, and Vss. Descriptive statistics (mean, median, range, standard deviation) for these parameters are provided and summarized by each dose group.
- Cmax and Tmax are determined from the plasma concentration-time profile, and tl/2[3 is calculated as 0.693/k (where k is the terminal elimination rate constant, calculated by log- linear regression of the terminal portion of the concentration-time profile).
- AUCO-t is calculated by the linear trapezoidal rule and extrapolated to infinity using k to obtain AUCO-oo.
- Pharmacokinetic parameters are calculated from compound (1) concentration-time data using standard non-compartmental methods as implemented in WinNonlin.
- the maximum plasma concentration (Cmax) and time to reach Cmax (Tmax) are the observed values.
- the area under the plasma concentration-time curve (AUC) value is calculated to the last quantifiable sample (AUClast) by use of the linear trapezoidal rule.
- the AUC values are extrapolated to infinity (AUCinf) by dividing the last quantifiable concentration by the terminal disposition rate constant (Xz), which is determined from the slope of the terminal phase of the concentration-time profile.
- the terminal half-life (Tl/2) is calculated as 0.693 divided by Xz.
- the apparent oral clearance (Cl/F) is calculated by dividing the dose administered by AUCinf.4.
- Pharmacokinetic data are analyzed by cohort.
- efficacy analysis The efficacy variable is best overall response (ORR), using RECIST criteria, version 1.1. Objective tumor response is tabulated and summarized by the primary tumor type. If warranted, additional efficacy endpoints, such as duration of response or time to progression, are analyzed.
- EXAMPLE 2 Study to Evaluate PK/PD results for a Pharmaceutical Composition Disclosed Herein for Treating a Disease in a Subject.
- Summary This study is a dose escalation study to investigate the safety, tolerability, and PK characteristics of in-patients with advanced solid tumors who have received and failed at least one prior treatment.
- the primary objective of this study is to assess the safety and tolerability of repeated daily dosing of 8-cyclopentyl-2-((4-(4-methylpiperazin-l- yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile (compound (1)) in patients with relapsed and/or refractory advanced cancers.
- the secondary objective of this study is to establish a MT of compound (1) and RP2D of orally administered compound (1).
- the study explores efficacy of compound (1) in cancer patients.
- Study design The study includes a treatment period (1 year) and a follow-up period (90 days after the last dose). Subjects are pathologically confirmed to have malignant solid tumors, or advanced (metastatic or unresectable) malignant solid tumors and have previously failed standard treatment (e.g., targeted therapy, chemotherapy, biotherapy, immunotherapy, etc.), as evidenced by disease progression or intolerance toxicity.
- standard treatment e.g., targeted therapy, chemotherapy, biotherapy, immunotherapy, etc.
- the study is divided into two stages, including a dosage escalation and a dose expansion cohort.
- the first phase is a dose escalation, using 3+3 design to determine MTD and/or RP2D.
- Three to six patients are enrolled per dose cohort, followed by up to 12 additional patients at the RP2D.
- Approximately 9-30 patients are enrolled in the first phase. If additional dose escalations are required to establish the MTD/RP2D, then 3-6 additional patients are added per dose level.
- Compound (1) is given in the form of a hard capsule comprising 48.4 mg 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile monolactate salt, equivalent to 40 mg of 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile.
- the dose (one capsule) is taken in the morning, on an empty stomach.
- Dose increments in the dose escalation 3+3 study are 40 mg of compound (1) per cycle. Dose levels are 40 mg, 80 mg, 120 mg, 160 mg, and 200 mg, or until a RP2D/MTD is reached. The highest escalation dose in the study is set at 200 mg. Dose escalation is performed as described in Example 1.
- the second stage of the study is a dose expansion stage.
- the dose expansion stage enrolls 9-12 cancer patients (primarily mantle cell lymphoma patients). Test procedures are the same as in the dose expansion phase.
- the primary objective of this study is to evaluate the tolerance, safety, and the antitumor efficacy of compound (1) in patients having advanced tumors.
- the secondary objective of this study is to characterize pharmacokinetics of compound (1) following oral administration of single and multiple doses of compound (1) in patients with relapsed and/or refractory advanced cancer. Secondary endpoints include maximum plasma concentration (Cmax), area under the plasma concentration time curve (AUC), and half-life (tl/2).
- Cmax maximum plasma concentration
- AUC area under the plasma concentration time curve
- tl/2 half-life
- the study evaluates the efficacy of compound (1) in patients with tumors, including objective response rate ORR, progression-free survival PFS, duration of remission DOR, disease control rate DCR, etc.
- PK pharmacokinetic
- Efficacy analysis The efficacy variable of this study is best overall response (ORR), using RECIST criteria, version 1.1.
- Efficacy analysis includes: (1) Objective Remission Rate (ORR), defined as the proportion of subjects with complete remission (CR) and partial remission (PR) after treatment.
- ORR Objective Remission Rate
- DCR Disease Control Rate
- SD disease stabilization
- DOR Time to remission
- PFS Progression free survival
- EXAMPLE 3 Dosing Regimen to Evaluate an Oral Pharmaceutical Composition Disclosed Herein with a BTK Inhibitor in a Subject
- the study is a randomized, double-blind, placebo-controlled, study of 8-cyclopentyl- 2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile (compound (1) in combination with a BTK inhibitor (e.g., ibrutinib or a pharmaceutically-acceptable salt thereof) versus placebo in combination with a BTK inhibitor (e.g., ibrutinib or a pharmaceutically-acceptable salt thereof) for patients with mantle cell lymphoma.
- a BTK inhibitor e.g., ibrutinib or a pharmaceutically-acceptable salt thereof
- Study Design This study is a treatment response study using 1 : 1 randomized doubleblind study. Patients are randomized into one of two treatment arms: Arm A: (placebo): ibrutinib-placebo combination therapy; and Arm B (experimental): ibrutinib-compound (1) combination therapy. Each cycle in the study is 28 days of treatment with tumors assessed every 12 weeks.
- Compound (1) is given in the form of a hard capsule comprising 48.4 mg 8- cyclopentyl-2-((4-(4-methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3- d]pyrimidine-6-carbonitrile monolactate salt, equivalent to 40 mg of 8-cyclopentyl-2-((4-(4- methylpiperazin-l-yl)phenyl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6- carbonitrile.
- Compound (1) is taken once daily for 28 days (one cycle). Alternatively, compound (1) is taken once daily continuously for 3 weeks with one week of no administration for a total of 28 days. Treatment continues until progression of disease or unacceptable toxicity. Compound (1) is taken in the morning, on an empty stomach.
- Ibrutinib or a pharmaceutically-acceptable salt thereof is given in the form of a 560 mg tablet.
- One 560 mg ibrutinib tablet is taken once on days 1-28 (one cycle). Treatment continues until progression of disease or unacceptable toxicity. Ibrutinib is taken in the morning with water, at the same time as either compound (1) or the placebo.
- Doses can be split into multiple dosage forms. For example, a 560 mg dose can be taken as two 280 mg tablets, four 140 mg tablets, or eight 70 mg tablets.
- ibrutinib is given in the form of a 420 mg tablet, a 280 mg tablet, a 140 mg tablet, a 140 mg capsule, or a 70 mg capsule. Doses can be split into multiple dosage forms. For example, a 280 mg dose can be taken as two 140 mg tablets or four 70 mg tablets. A 140 mg dose can be taken as two 70 mg tablets.
- a dose of One ibrutinib tablet or one ibrutinib capsule is taken once on days 1-28 (one cycle). Treatment continues until progression of disease or unacceptable toxicity. Ibrutinib is taken in the morning with water, at the same time as either compound (1) or the placebo.
- Primary outcome measures Primary outcome measures are increase in Progression- Free Survival (PFS) in experimental arm versus comparator arm.
- OS Overall survival
- Toxicity Incidence and severity of adverse events by summaries of toxicity data/contingency tables.
- Toxicity/efficacy of the various compounds of the disclosure are analyzed and compared.
- Treatment effect was measured by CellTiter-Glo proliferation assay, FACS-mediated quantification of cell cycle and apoptosis, RT-PCR, and western blot validations.
- Compound (1) exhibited significant antitumor activity in MCL cell lines independent of their sensitivity to ibrutinib with calculated half maximal inhibitory concentration (IC50) at 72 hours ranging for 0.7 to 7.1 pM (mean 3.61 ⁇ 2.1 pM) (Table 2).
- Compound (1) was more potent in MCL cell lines than the CDK inhibitors Palbociclib and riboci clib (mean IC50 26.92 pM and 20.91 pM, respectively) and was similarly potent as abemaciclib (6.56 pM) (Table 2).
- Compound (1) treatment repressed the activity of positive regulators of the G2/M cell cycle (Aurora kinase B, CDC20, CDK1, and cyclin B); decreased phosphor-Histone H3 levels, increased levels of the CDK inhibitors p21, pl6, and CDK2 phosphorylation resulting in a 20-35% increase in the G1 cell cycle fraction at 24 hours that preceded the onset of mitochondrial apoptosis.
- the antitumor activity of compound (1) was similar to that of ibrutinib but more potent than acalabrutinib.
- Combination treatment with compound (1) and ibrutinib resulted in antitumor activity at 72 hours with synergistic combination indexes in BTK-sensitive and BTK-resistant MCL cell lines, resulting from a 10-15% augmentation of G1 blockade at 24 hours, downregulation of phospho-histone H2 and phospho-CDK2, and upregulation of phospho-p27/p27 and pl 6.
- Efficacy and safety of compound (1) was assessed in an immune-competent, chicken embryo chorioallantonic membrane (CAM) xenograft model of MCL.
- Compound (1) treatment resulted in 32% tumor growth inhibition in the CAM-MCL model with no detectable toxicity observed.
- MCL mantle cell lymphoma
- the target protein expression for phosphorylated retinoblastoma protein (pRb), Rb, CDK4, and CDK6 proteins were determined by western blot analysis in MCL cell lines JEKO, UPN-1, REC-1, MINO, GRANTA-519, Z-138, and the modified counterpart MCL cell lines UPN-ibrutinib resistant, REC-1 BTK mutant, and REC-1 BTK KO (FIG. 3).
- Cell viability was quantified by CellTiter-Glo ⁇ (CTG) proliferation assay in MCL cell lines JEKO, UPN-1, REC-1, MINO, GRANTA-519, and Z-138, treated with increasing doses of Compound (1) for 72 hours (FIG. 4). Cell viability decreased with increasing concentrations of Compound (1).
- CCG CellTiter-Glo ⁇
- MCL mantle cell lymphoma
- CI values were calculated using the Compusyn Software (Chou-Talalay method) from CTG proliferation assays of MCL cell lines treated with different doses of Compound (1) combined with BTK inhibitors ibrutinib (FIG. 6) or acalabrutinib (FIG. 7).
- 0.5pM CDK4/6 inhibitor e.g., Compound (1), abemaciclib, and palbociclib
- IpM BTK inhibitor e.g., ibrutinib, acalabrutinib, and Loxo-305
- REC-1 BTK mutant FIG. 12
- 0.5pM CDK4/6 inhibitor e.g., Compound (1), abemaciclib, and palbociclib
- IpM BTK inhibitor e.g., ibrutinib, acalabrutinib, and Loxo-305
- Compound 1 exhibited superior activity to comparator CDK inhibitors. Compound 1 exhibited significant antitumor activity in MCL cell lines, independently of sensitivity to BTK inhibitors. Combination of CDK4/6 inhibitor Compound (1) with BTK inhibitors ibrutinib or acalabrutinib were found to be synergistic in MCL cell lines.
- EXAMPLE 7 Evaluation of cell cycle activity of Compound (1) in combination with CDK inhibitors palbociclib, abemaciclib, or ribociclib in association with BTK inhibitors ibrutinib, acalabrutinib, or Loxo-305
- Apoptosis analysis was assessed by AnnexinV+ staining (FIGs. 20-21) and mitochondrial transmembrane potential loss (FIGS. 22-23) after treatment with Compound (1) (0.5pM) alone and in combination with combined with BTK inhibitors ibrutinib (IpM) or acalabrutinib (IpM) for 72 hours.
- Compound (1) evokes a G1 cell cycle blockade.
- the blockade by was improved when Compound (1) was combined with BTK inhibitors.
- Gene-set enrichment analysis was performed to identify the types of proteins with an altered pattern of gene expression.
- An enrichment analysis of the differentially expressed genes was performed.
- Enrichment analysis was performed in relation to detected genes.
- groups were analyzed in terms of characterization, including by gene ontology (GO) biological process.
- Treatment with Compound 1 was found to modulate various genes in MCL, including G2/M checkpoints, E2F target genes, MYC target genes, DNA repair, TNFa signaling via NFKB, and inflammatory response.
- Compound (1) treatment resulted in 32% tumor growth inhibition in the CAM-MCL model (FIG. 45) with no detectable toxicity observed according to egg weights of eggs inoculated with CDK4/6 inhibitor and/or ibrutinib (FIGs. 46-47) or embryo weight at day 7 following treatment with CDK4/6 inhibitor and/or ibrutinib (FIG. 48).
- Toxicity assays including determinations of egg weights and embryo weights, were conducted.
- Compound (1) exhibited significant anti-tumor activity that was improved when combined with ibrutinib in a in vivo CAM xenograft model of MCL.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Est présentement divulguée une méthode de traitement d'un lymphome par l'administration de 8-cyclopentyl-2-((4-(4-méthylpipérazin-1-yl)phényl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile ou d'un sel pharmaceutiquement acceptable de celui-ci, seul ou en combinaison avec un deuxième agent tel qu'un inhibiteur de BTK, par exemple l'ibrutinib, l'acalabrutinib, ou un sel pharmaceutiquement acceptable de celui-ci. Sont également divulgués des combinaisons de 8-cyclopentyl-2-((4-(4-méthylpiperazin-1-yl)phényl)amino)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidine-6-carbonitrile ou d'un sel pharmaceutiquement acceptable de celui-ci, et d'un deuxième agent tel qu'un tel inhibiteur de BTK, par exemple l'ibrutinib ou un sel pharmaceutiquement acceptable de celui-ci ou de l'acalabrutinib ou un sel pharmaceutiquement acceptable de celui-ci.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263345630P | 2022-05-25 | 2022-05-25 | |
US63/345,630 | 2022-05-25 | ||
US202263426235P | 2022-11-17 | 2022-11-17 | |
US63/426,235 | 2022-11-17 | ||
US202363496301P | 2023-04-14 | 2023-04-14 | |
US63/496,301 | 2023-04-14 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2023230286A2 true WO2023230286A2 (fr) | 2023-11-30 |
WO2023230286A3 WO2023230286A3 (fr) | 2024-01-11 |
WO2023230286A9 WO2023230286A9 (fr) | 2024-04-04 |
Family
ID=88919918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/023618 WO2023230286A2 (fr) | 2022-05-25 | 2023-05-25 | Méthodes et compositions pour le traitement du cancer |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023230286A2 (fr) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160022684A1 (en) * | 2014-07-25 | 2016-01-28 | Pharmacyclics Llc | Bet inhibitor and bruton's tyrosine kinase inhibitor combinations |
CA3011949A1 (fr) * | 2016-03-15 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Methodes de traitement du cancer du sein er+, her2-hrg+ a l'aide de traitements d'association comportant un anticorps anti-erbb3 |
CN112969463A (zh) * | 2018-11-12 | 2021-06-15 | 安哥洛华治疗公司 | 8-环戊基-7-氧代-2-(4-哌嗪-1-基-苯基氨基)-7,8-二氢-吡啶并[2,3-d]嘧啶-6-腈及其在治疗增殖性疾病中的用途 |
US20220401442A1 (en) * | 2019-11-04 | 2022-12-22 | Astrazeneca Ab | Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies |
-
2023
- 2023-05-25 WO PCT/US2023/023618 patent/WO2023230286A2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023230286A9 (fr) | 2024-04-04 |
WO2023230286A3 (fr) | 2024-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI831916B (zh) | 包含tno155和瑞博西尼之藥物組合 | |
EP3076977B1 (fr) | Polythérapie pour le traitement du cancer | |
US20190192522A1 (en) | Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors | |
US11938124B2 (en) | Combination therapy for treatment of cancer | |
RU2738934C2 (ru) | Способы лечения рака с использованием апилимода | |
US9295676B2 (en) | Mutation mimicking compounds that bind to the kinase domain of EGFR | |
KR20160070188A (ko) | 암치료에 유용한 tie2 키나아제의 억제 방법 | |
JP6944936B2 (ja) | 血液癌を処置するためのセルデュラチニブ | |
US20240082218A1 (en) | Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers | |
TW201943428A (zh) | 預防或治療腫瘤療法副作用的方法 | |
JP2020114849A (ja) | Egfr依存性疾患またはegfrファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における2−カルボキサミドシクロアミノウレア誘導体の使用 | |
JP2018520117A (ja) | B細胞悪性腫瘍の治療のためのセルデュラチニブ | |
TW202317100A (zh) | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 | |
US20210330612A1 (en) | Methods for treating cancer resistant to cdk4/6 inhibitors | |
WO2013086002A1 (fr) | Compositions, procédé de préparation de ladite composition et méthode de traitement du cancer | |
Konar et al. | Synthesis and clinical development of Palbociclib: an overview | |
KR102337598B1 (ko) | 암 치료 방법 | |
EP4433061A1 (fr) | Méthodes et compositions pour traitement du cancer | |
WO2023230286A2 (fr) | Méthodes et compositions pour le traitement du cancer | |
US20080139480A1 (en) | Combination Of (A) N--4-(3- Pyridyl)-2-Pyrimidine-Amine And (B) At Least One Hypusination Inhibitor And The UseThereof | |
CA3238360A1 (fr) | Methodes et compositions pour traitement du cancer | |
US11202792B2 (en) | CD99 inhibitors and their uses | |
WO2024107955A1 (fr) | Méthodes et compositions pour le traitement du cancer | |
WO2023230288A1 (fr) | Méthodes et compositions pour le traitement du cancer | |
WO2023230220A2 (fr) | Méthodes et compositions pour le traitement du cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23812601 Country of ref document: EP Kind code of ref document: A2 |